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Depression and cardiovascular disease are two of the leading causes of disability and death in the 
U.S. and worldwide, respectively.  Both health disparities are frequently managed and treated 
with conventional medicine using drugs that may increase the pain and suffering of patients due 
to unwanted side-effects, thereby likely prompting patient nonadherence to physician guidance 
and pharmaceutical interventions.  This study aims to determine the effects of various non-
pharmaceutical therapies including psychotherapy, exercise therapy, meditation, and acupuncture 
with musical therapy, and their influence on depression and cardiovascular disease.  The main 
question in this review asks: do non-pharmaceutical therapies have positive effects on depression 
and cardiovascular disease?  The results indicate that several non-pharmaceutical interventions 
do have positive effects on depression and cardiovascular disease, and can even be as effective as 
antidepressants for the treatment of depression, when used alone or in combination with 
conventional medical practices.  While the current research on non-pharmaceutical therapy for  
depression and cardiovascular disease is promising, additional studies are needed to gain a 
complete understanding of this influence.  The intent of this review was also to encourage the 
health care community to implement a multidisciplinary and integrative approach to treating 
depression and heart disease, which are frequently comorbid and bidirectional, where the 
alleviation of one condition should prompt the recovery from the other.  
Keywords: non-pharmacotherapy, non-pharmacologic therapy, psychotherapy, depression, 
mental health, mental illness, cardiovascular disease, cognitive behavior therapy, heart disease, 
major depressive disorder 
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What is the Role of Non-Pharmacotherapy in the Treatment of 
Depression with Cardiovascular Disease? 
Chapter 1 
Introduction 
Depression and cardiovascular disease are two of the most common health conditions in 
the United States and worldwide (NIMH, 2017; WHO, 2018).  Depression, also referred to as 
clinical depression or major depressive disorder (MDD), is a serious and treatable mental health 
condition in which individuals experience feelings of sadness and/or a loss of interest in 
activities that were once enjoyed (American Psychiatric Association, 2013).  Major depressive 
disorder is diagnosed in individuals who experience such feelings of sadness for a period of at 
least two weeks.  While depression refers to a disturbance in the emotional or psychological 
state, cardiovascular disease refers to a pathophysiological problem with the heart and blood 
vessels.  According to the American Heart Association (2017), cardiovascular disease (CVD), 
also called coronary artery disease (CAD), refers to diseases affecting the heart and/or 
circulatory system and consists of various conditions including myocardial infarction, stroke, 
heart failure, angina, hypertension, arrhythmia, atherosclerotic calcification, and/or heart valve 
problems (Mezick et al., 2010).  
Major depression is known to be more prevalent in people who have experienced a major 
cardiac event, with up to 40% of patients meeting the DSM-V criteria for major depressive 
disorder (MDD) (Dhar & Barton, 2016).  The large European Action on Secondary Prevention 
through Intervention to Reduce Events (EUROASPIRE) study showed even higher rates of 
people with cardiovascular disease suffering from comorbid depression, with up to 35% of men 
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and up to 65% of women measured on the hospital anxiety and depression scale (Dhar & Barton, 
2016).   Another trial called the enhancing recovery in coronary heart disease (ENRICHD) 
assessed data on patients who had recently suffered a myocardial infarction and found that 
depression was diagnosed in a staggering 74% of these patients (Dhar & Barton, 2016).  While 
data shows that an average of 10% of the general population who are hospitalized in general 
practice clinics suffer from major depression, this percentage increases up to 30% in those with 
coronary heart disease (CHD) in outpatient clinics, and up to an overwhelming 50% in those who 
are in inpatient settings recovering from coronary artery bypass surgery (Dhar & Barton, 2016). 
The high prevalence of both depression with heart disease begs the question of the 
possible links between the two health variables.  Depression now affects 1 in 15 people or 6.7% 
of the population in the U.S. and between 3.3% and 21.4% of the global population in both 
developed and developing countries.  Additionally, depression “produces the greatest decrement 
in health compared with chronic diseases such as angina, arthritis, asthma, and diabetes.  The 
comorbid state of depression incrementally worsens health compared with depression alone, with 
any of the chronic diseases alone, and with any combination of chronic diseases without 
depression” (Moussavi et al., 2007).  With regard to heart disease, for nearly 15-years 
cardiovascular disease has persisted as the leading cause of death in the U.S. and worldwide, 
with ischemic heart disease accounting for 635,260 and 8,756,006 deaths each year, respectively 
(NIH, 2017; Quirk et al., 2013; WHO, 2018).  Recent research on the health effects of depression 
strongly suggests that mental illness contributes to an increased risk of cardiovascular disease 
and can be associated with severe cardiovascular consequences (Chaddha, Robinson, Kline-
Rogers, Alexandris-Souphis, & Rubenfire, 2016).  Certain measures to manage and treat 
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depression and heart disease utilizing non-pharmaceutical therapies should be considered for 
their benefits on the psychological and cardiovascular health of patients.   
Significance of the Study 
 A major underlying contributor to the high prevalence of depression and cardiovascular 
disease around the world may be the evidence of nonadherence to pharmacotherapy most often 
prescribed in conventional medicine for both disease states.  The extent of nonadherence to 
medication varies widely, and “in different studies it has been recorded as low as 10 percent and 
as high as 92%.  Extensive review of the literature reveals that in developed countries adherence 
to therapies averages 50%” (Beena & Jimmy, 2011).  Studies show that patients are most non-
compliant for chronic diseases, such as hypertension (Beena & Jimmy, 2011).  Poor adherence to 
medication regimen has been particularly shown to increase the risk of depression, and patients 
have a 10-fold increased risk for myocardial infarction and stroke, as compared to patients who 
follow physician guidance (Chaddha et al., 2016; Lustman & Clouse, 2005).  In addition, 
nonadherence substantially worsens disease, increases risk of death, and increases healthcare 
costs (Beena & Jimmy, 2011).  According to the American Medical Association (2015), there are 
several reasons for patient nonadherence to physician guidance and prescribed medications 
including: a fear of potential side-effects, high cost; a misunderstanding for the need of the 
medication; the patient is already taking too many medications; a lack of symptoms; concerns 
about becoming dependent on the medication; depression; and a distrust of the physician 
prescribing the medication.  The fear of side-effects and dependence, as well as the high cost of 
medication are the main deterrents of medication adherence for patients, yet this could be 
circumvented with the use of more non-pharmaceutical treatment options (American Medical 
Association, 2015).  Through the implementation of various forms of non-pharmaceutical 
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techniques to treat mental illness and cardiovascular disease, traditional pharmacotherapy and the 
increased risk of serious adverse events due to noncompliance may be avoided—unless 
medication is otherwise indicated for the patient where an integrative approach to treatment may 
be optimal.  For this reason, it is important to further investigate the effects of non-
pharmacotherapy on depression and cardiovascular disease to better understand the appropriate 
utilization of non-pharmacological disease management in the scientific and healthcare 
community.  Furthermore, increasing the awareness of depression and cardiovascular disease 
within the scientific and medical community is imperative for the proper diagnosis, management, 
and treatment of these health conditions. 
This review of literature investigates the effects of various non-pharmacologic therapies 
on depression and cardiovascular disease and seeks to determine whether common forms of non-
pharmacotherapy have positive effects on reducing the symptoms of depression and 
cardiovascular disease in patients. 
  




Review of the Literature 
Depression and Cardiovascular Disease 
 Recent interest has been dedicated to investigating the relationship between depression 
and cardiovascular disease in different populations.  In their article, authors Chaddha et al. 
(2016) discuss the link between mental health and cardiovascular disease.  According to 
Chaddha et al. (2016), the American Heart Association has concluded that depression has the 
strong potential to accelerate atherosclerosis as well as “promote the onset and severity of the 
coronary risk factors for diabetes, hypertension, and high levels of low-density lipoprotein.”  The 
mechanisms most contributory to an increase in cardiac risk factors through depression is due to 
lifestyle factors and the lack of compliance with recommended treatments by the patient 
(Chaddha et al., 2016).  Patients with depression or those who experience various symptoms of 
depression are more likely to engage in unhealthy lifestyle habits including smoking; consuming 
diets high in calories, salt, and saturated fats; and are less likely to be physically active and 
adhere to prescribed or suggested medications (Chaddha et al., 2016).   
Alcohol use disorder has also been strongly associated with both depression and 
cardiovascular disease.  According to Christy, Anithakumari, and Biju (2017), “a significant 
number of alcohol use disorder patients also suffer from other psychiatric disorders including 
mood disorders, anxiety disorders, personality disorders, and schizophrenia,” especially 
depression.  The severity of depression corresponds to the severity of the alcohol abuse of 
patients (Christy et al., 2017).  However, heavy drinking (>2.5 drinks/day for women, 
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>4/drinks/day for men) is associated with an increased risk of cardiovascular disease and death 
((O’Keefe, DiNicolantonio, O’Keefe, & Lavie, 2018).  Even when men and women drink in 
moderation, the occasional binge drinking episode offsets the positive effects of moderate 
drinking (O’Keefe et al., 2018).  They also state that “heavy alcohol use is a common cause of 
reversible hypertension (HTN), nonischemic dilated cardiomyopathy, atrial fibrillation (AF), and 
stroke (both ischemic and hemorrhagic).”  Ethanol itself is a well-documented cardiotoxin if 
consumed at excess doses.  Evidence also suggests that genetic polymorphisms in the aldehyde-
dehydrogenase-2 gene plays a significant role in cardiovascular disease as “alcohol oxidase 
(AOX) is the first enzyme in the methanol utilization pathway and is encoded by two genes, 
aldehyde-dehydrogenase-1 (ADLH1) and aldehyde-dehydrogenase-2 (ADLH2)” (Cregg, 
Madden, Barringer, Thill, & Stillman, 1989).  Most of the research investigating the effects of an 
atypical allele for ADLH2 on cardiovascular disease uses the Asian population, since this 
demographic has a high prevalence of the genetic variation for this gene (Chuan, 2004).  
According to Luo and Zhang (2004), an atypical ADLH2 gene leads to high alcohol sensitivity 
and flushing post-drinking.  Also, atypical ADLH2 produces a greater risk for alcohol induced 
liver injury ischemic heart disease (Chuan, 2004).  ADLH2 is a multifunctional enzyme that 
catalyzes the oxidation of aldehydes that is shown to cause mitochondrial cell death and 
apoptosis (Liu & Sun, 2017).  In addition, consuming 14 or more drinks per week has been 
shown to increase blood pressure in a dose-dependent fashion and any drink above 2 drinks per 
day increases blood pressure by 1.5 mm/Hg (O’Keefe et al., 2018).  With the cessation or drastic 
reduction of alcohol consumption, alcohol-induced hypertension typically resolves within 2-4 
weeks.  O’Keefe et al. (2018) state that chronic heavy alcohol consumption is also an 
independent risk factor for stroke and “a recent meta-analysis of 27 prospective studies reported 
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that light and moderate alcohol intakes were associated with a lower risk of ischemic stroke, 
whereas heavy drinking was associated with an increased risk of both ischemic and hemorrhagic 
strokes.”  These unhealthy lifestyle factors each independently increase the risk for 
cardiovascular disease.   
Furthermore, patients who do not follow their physician’s lifestyle and medication 
recommendations have a 10-fold increased risk for myocardial infarction and stroke, as 
compared to patients who follow physician guidance (Chaddha et al., 2016).  Chaddha et al. 
(2016) assert that “there is about an 80% increase in the risk of developing new or worsening 
cardiovascular disease (i.e., more complications or hospitalizations), as well as death from
cardiovascular diseases in adults with depression with or without prior cardiovascular disease.  
Depression is also common in patients who have angina and can increase the risk of developing 
myocardial infarction, stroke, sudden death, and atrial fibrillation.”  For this reason, the 
importance of patient compliance with physician guidance for the treatment and prevention of 
both depression and cardiovascular disease should not be underestimated.   
 While depressed patients have an increased risk of cardiovascular disease due to lifestyle 
factors and a lack of compliance with treatment recommendations, depression also poses changes 
in the physiological health of the patient.  Depression has been shown to increase circulating 
cortisol levels within the body—a stress hormone known to increase blood glucose levels, cause 
weight gain, lower high-density lipoproteins (HDL or “good” cholesterol), as well as increase 
blood pressure in patients (Chaddha et al. 2016).  Patients with depression have also been shown 
to have higher levels of other circulating hormones, including parathyroid hormone, (Witte et al., 
2008).  According to an article by Grof, Brown, Grof, and Finkelberg (1980), studies have shown 
a strong correlation between depression and abnormal neuroendocrine function and “it has been 
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shown that the neurotransmitter systems that are implicated in the psychobiological mechanisms 
of affective disorders are involved in the regulation of neuroendocrine function.”  Additionally, 
Grof et al. (1980) state that “abnormalities of neuroendocrine function in depressed patients 
include consistent changes in plasma and urinary cortisol… and in the responsiveness of growth 
hormone (GH) and thyroid-stimulating hormone.”  Increased levels of adrenaline in depressed 
patients have also been linked to an increased resting heart rate, blood pressure, and heart rate 
response to exertion in patients each may also increase the risk of myocardial infarction, 
arrhythmias, heart failure, and mortality (Chaddha et al., 2016).  According to Chaddha et al. 
(2016), “inflammation and poor dental hygiene, pneumonia, surgical procedures, and arthritis 
increase the risk for heart attacks.  Depression may also lead to increased platelet activity, 
increasing the risk of coronary artery occlusion.”  Poor dental hygiene has been associated with 
aggravated systemic inflammation through the higher levels of inflammatory circulating 
molecules including adiponectin, fibrinogen, C-reactive protein (CRP) and cellular adhesion 
molecule-1 (sICAM-1) (Frisbee, Chambers, Frisbee, Goodwill, & Crout, 2010).  A study by 
O’Neil, Berk, Venugopal, Kim, Williams, and Jacka (2014) asserts that poor dental hygiene is 
also associated with depression.  In their article, O’Neil et al. (2014) state that “poor oral hygiene 
is associated with a 70% increased risk of CVD, while periodontal disease is associated with a 
two-fold increase in the risk of CVD-related mortality. There is now abundant evidence that 
depression is also an inflammatory disorder. This high prevalence condition is accompanied by 
chronic, low-grade inflammation, indicated by increased levels of acute-phase proteins, such as 
C-reactive protein (CRP), as well as pro-inflammatory cytokines including interleukins and 
tumor necrosis factor (TNF).”  Furthermore, elevated levels of inflammatory markers including 
C-Reactive protein, increase the risk of developing major depressive disorder (O’Neil et al., 
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2014).  Thus, poor dental hygiene is indicated in both cardiovascular disease and major 
depression.   
According to Yeh, Cheng-Li, and Kao (2018), pneumonia is linked to a higher risk of 
cardiovascular disease particularly heart failure, “regardless of age, gender, comorbidities, and 
antibiotic use, particularly in elderly male patients [because] streptococcus pneumoniae infects 
the myocardium and induces necroptosis and apoptosis, which are followed by cardiac scarring 
and heart failure.  Chlamydia pneumoniae and mycoplasma pneumoniae, and the oxidative stress 
caused by these infections are associated with atherosclerosis in patients with CVDs” (Yeh et al., 
2018).  Moreover, patients diagnosed with valvular heart disease who undergo non-cardiac 
surgery have a heightened risk for perioperative cardiovascular risk depending on the severity of 
the disease (Mutlak, Humpich, Zacharowski, Lehmann, & Meininger, 2011).  In the most 
common form of valvular heart disease, the volume or pressure load of the left ventricle and left 
atrium typically occurs—thus increasing the patient’s risk for heart failure.  
Psychosomatic research frequently suggests a strong link between coronary heart disease 
(CHD) and mental disorders.  An article by Chauvet-Gélinier, Trojak, Vergès-Patois, Cottin, and 
Bonin (2013) discusses how advancements in medical technology including 
immunohistochemistry, functional imaging, and genetics has made it possible to verify how 
coronary heart disease and mental illness, mood disorders in particular, are interrelated (Chauvet-
Gélinier et al., 2013).  Immunohistochemistry has become an indispensable technique used to 
detect and assess the distribution of proteins in cells of tissues, especially in the carotid body 
(CB)—a distinct area of the carotid artery that runs along both sides of the throat (Huang, 
Naduri, Prabhakar, & Walker, 2018).  One novel and promising form of functional imaging is 
the diffuse optical spectroscopic imaging (DOSI)—a non-invasive assessment tool that detects 
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“silent” cardiovascular disease and cardiovascular disease risk.  According to Warren (2017) 
“DOSI is a quantitative, model-based technique that utilizes a broadband wavelength range, 
corrects for light scattering, and probes several centimeters into tissue.  DOSI is particularly 
relevant for cardiovascular disease research because it measures absolute concentrations of the 
primary light absorber in blood, hemoglobin, as well as the oxygenation state of hemoglobin, 
lipid content, and water content.”  DOSI makes it possible for hemodynamic measurements, 
compositional analysis, and reliable comparisons across operators, instruments, and separate 
institutions (Warren, 2017).  With the advancements of medical technologies (MT), increasing 
attention has been directed towards genetic testing for risk of cardiovascular disease.  Next-
generation sequencing (NGS-based genetic testing) allows for the “simultaneous testing of all 
genes associated with any cardiovascular phenotype and molecular genetic testing for multiple 
genes has become the standard of practice for cardiovascular medicine” (Schmidtke, Wittkowski, 
& Glaubitz, 2019).  There are several advantages to NGS-based genetic testing including 
increased cost-efficiency, heightened clinical sensitivity, and the increased sensitivity for 
detecting non-Mendelian phenomena including digenic inheritance (Schmidtke et al., 2019).  
Genetic testing can also provide insight into the hereditary components of depression.  The 
heritability of major depressive disorder is estimated to be around 40% (Opmeer, Kortekaas, & 
Aleman, 2010).  According to Opmeer et al. (2010), the dopamine theory of affective disorders 
suggests that a deficiency in dopamine release from presynaptic neurons, impaired signalling, 
and disturbed catabolism synthesis of dopaminergic transmission could play a significant role in 
the major symptoms of major depressive disorder.  Opmeer et al. (2010) state that: 
“The biosynthesis of dopamine depends on availability of the amino acid tyrosine, which 
is converted to dihydroxyphenylalanine (dopa) by the enzyme tyrosine hydroxylase.  
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Subsequently, the enzyme dopa decarboxylase (DDC) rapidly catalyzes formation of 
dopamine from dopa.  Every biochemical step in the neurotransmission and metabolism 
of dopamine corresponds to a specific enzyme, encoded for by a corresponding gene. 
Polymorphisms in these genes could have major implications for dopamine metabolism 
and neurotransmission and consequently cause neuropsychiatric disorders like MDD.”  
Therefore, NGS-based genetic testing could be advantageous for the proper diagnosis of both 
depression and cardiac disorders.   
Heart disease and mood disorders are most often comorbid states of illness, with one 
disease usually worsening the other, and vice-versa.  The bidirectional relationship between 
coronary heart disease and mood disorders has triggered various psychological, biological, and 
genetic arguments for the relationship between these health conditions (Chauvet-Gélinier et al., 
2013).  According to Chauvet-Gélinier et al. (2013), “epidemiological studies have shown that 
depression is a psychic risk factor for coronary heart disease and that coronary heart disease is 
present in almost 30% of patients with affective disorders.”  Furthermore, Chauvet-Gélinier et al. 
(2013) discuss how the natural human stress response to stressful situations may become 
prolonged leading to the potential for a depressive state in the patient.  This depressive state as a 
result of stress may then lead to physiopathological alterations of the heart.   
It is equally important to recognize the adverse effects of blood sugar imbalance with 
mood regulation and the increased incidence of depression “particularly operational in type 1 
diabetes, wherein the onset of diabetes antedates the first presentation of depression by many 
years” (Lustman & Clouse, 2005).  Research shows that hyperglycemia can promote and 
exacerbate symptoms of anxiety in patients suffering from type I diabetes (Lustman & Clouse, 
2005).  Moreover, Lustman and Clouse (2005) state that in “a study that prospectively examined 
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the relationship between blood glucose levels and self-reported mood in adults with type 1 
diabetes, negative mood states, including anger and sadness, were related to high blood glucose 
levels in the majority of patients.”  Thus, the effects of glucose dysregulation, particularly 
hyperglycemia, including cortisol abnormalities, weight gain, physical inactivity, and the poor 
adherence to medication regimen—have all been shown to increase the risk of depression in 
patients, though the directional relationship has not yet been fully established (Lustman & 
Clouse, 2005).   
Research also suggests an association between hypoglycemia, depression, and sleep 
quality in patients with type II diabetes.  A meta-analysis by Biggers et al. (2019) discusses how 
poor sleep quality, excessive daytime sleepiness, and depressive symptoms are related to 
hypoglycemia, which is recognize as a relationship “that may be complex, bidirectional, and 
reflect poor self-care, non-adherence to diet or glucose self-monitoring.”  Hypoglycemia is 
defined as experiencing episodes of low blood sugar and usually mild symptoms including 
sweating, trembling, or difficulty concentrating (Biggers et al., 2019).  Results of their study 
indicated that adults with type II diabetes in Chicago and Thailand who had a history of 
hypoglycemia were more likely to experience poor sleep quality and higher depressive 
symptoms in bivariate analysis.  Furthermore, subjects from Thailand had “more depressive 
symptoms were associated with more frequent hypoglycemia, adjusting for insulin and 
sulfonylurea use as well as duration of diabetes” (Biggers et al., 2019)  Thus, a correlation 
between poor glucose control and depression has been shown to exist for in both hyperglycemia 
and hypoglycemia.   
According to Lustman and Clouse (2005), psychotherapy and pharmacotherapy are both 
effective for the treatment of diabetes; “both cognitive behavior therapy and selective serotonin 
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reuptake inhibitors are weight neutral and have been associated with glycemic improvement in 
some studies.”  The exact nature explaining the comorbidity of depression and coronary heart 
disease has not yet been clearly established.  However, the INTERHEART study reported that 
depression as a psychic factor and psychosocial stressor is the third leading risk factor for 
coronary artery disease behind apolipoprotein ratio B/apolipoprotein A1 and smoking.  
Depression also has a higher risk ratio for coronary heart disease compared to diabetes, arterial 
hypertension and abdominal obesity and evidence indicates that treating a comorbid affective 
disorder can decrease substance abuse and craving in patients (Chauvet-Gélinier et al. 2013; 
Quello, Brady, & Sonne, 2005).    
Interestingly, personality type has been shown to increase one’s risk of developing 
coronary artery disease due to adverse long-term biological mechanisms within the body.  
Chauvet-Gélinier et al. (2013) describe how people with type A personality characterized by 
intense activity, a desire to do things quickly and combativeness “that may lead to hostile 
attitudes in order to reach fixed objectives.  The behavior pattern of type A people confers great 
vulnerability to depression.”  Furthermore, people with type A personality are more likely to 
develop depression and coronary heart disease as a result of mood disorders as a response to 
unwanted life circumstances including being unrecognized at work, unemployment, or social 
isolation (Chauvet-Gélinier et al., 2013).  Also, patients who have suffered from myocardial 
infarction are more likely to have type A personalities (Chauvet-Gélinier et al., 2013).   
Likewise, these people are also more inclined to suffer from mood disorders, usually major 
depressive disorder (Chauvet-Gélinier et al., 2013).  Another article by Rugulies (2002) 
discusses how the plethora of research assessing the association between depression and cardiac 
health blames the effects of depression on cardiovascular disease on behavior patterns—
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particularly the type A personality type and the tendency for these people to “wear themselves 
down.” Rugulies (2002) describes the type A personality as individuals who display hard-driving 
behavior, including competitiveness and chronic feelings of time-urgency—which is 
acknowledged by the scientific community as an independent risk factor for coronary heart 
disease.  In recent years, the continued investigation on psychic disorders and cardiovascular 
disease has shed light onto the revelation that “depression is a predictor for survival after 
myocardial infarction” (Rugulies, 2002).   
Lifestyle factors have also been shown to increase the risk of cardiovascular disease.  
Chauvet-Gélinier et al. (2013) describe the behavioral impact of depression on the negative 
evolution of heart disease.  People who are depressed are characterized by a loss of interest in 
activities, a lack of motivation to do things they once enjoyed, and generalized feelings of 
malaise and sadness.  Those who are depressed are less likely to feel motivated to change 
unhealthy daily habits, such as smoking, consuming high-calorie foods, and are unable to muster 
the energy to maintain physical fitness.  Unfortunately, depression “may occur at any time during 
a person’s history of coronary artery disease and is a behavioral factor in the development or 
aggravation of heart disease as the patient adopts a prolonged sedentary lifestyle, experiences a 
decline in psychological and physical motivation and tends not to respect the therapeutic 
regimen” (Chauvet-Gélinier et al., 2013).  Additionally, symptoms of depression increase the 
risk of developing metabolic syndrome especially among middle-aged women (Chauvet-Gélinier 
et al., 2013).  Metabolic syndrome is a cluster of conditions including hypertension, 
dyslipidemia, elevated fasting blood glucose, and abdominal obesity (Levine et al., 2017).  
Moreover, changes in metabolism as a result of depression increase the risk of coronary artery 
disease in this population.    
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A study by Ornish et al. (1990) investigated whether comprehensive lifestyle changes 
affect coronary atherosclerosis.  A group of 48 patients with angiographically documented 
coronary artery disease between the ages of 35 and 75 years were assigned to one-of-two groups.  
A total of 28 subjects were assigned to an experimental group where subjects were required to 
follow low-fat vegetarian diets, smoking cessation, stress management training, and moderate 
exercise for at least one year.  The second group of 20 patients were assigned to a usual-care 
control group.  Selective coronary angiography was done using the percutaneous femoral 
technique.  Blood samples to measure serum lipids were drawn at baseline, after 6 months, and 
after one year.  Nutrient intake and dietary adherence were assessed using a 3-day diet diary at 
baseline and after one year.  Stress management techniques were given for at least one-hour per-
day with an audiocassette tape to assist in stretching exercises, breathing techniques, meditation, 
progressive relaxation, and imagery (Ornish et al., 1990).  Patients were asked to participate in 
daily physical exercise and advised to reach a target training heart rate of 50-80% of their heart 
rate at baseline.  Subjects were asked to engage in 3 hours of physical exercise (walking) each 
week in 30-minute increments.  Patients in the experimental group also participated in twice-
weekly group discussions in which a clinical psychologist provided social support to patients to 
help them adhere to these lifestyle changes, enhance communication skills, and to talk about 
their feelings about relationships, work, and home life (Ornish et al., 1990).   
After the evaluation of the various measures for serum lipids, coronary atherosclerosis 
through angiography, diet diary, and physical exercise performance, results of Ornish et al.’s 
(1990) study concluded that lifestyle changes have a significant positive effect on cardiovascular 
health.  A total of 84% of patients in the experimental group who engaged in lifestyle changes 
had a regression of coronary atherosclerosis, where the average percentage diameter stenosis 
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regressed from 61.1 mm to 55.8 mm.  However, the usual-care group experienced a worsening of 
coronary atherosclerosis since percentage diameter of stenosis increased by an average of 61.7 
mm to 64.4 mm at the end of one year (Ornish et al., 1990).  Furthermore, the degree of 
adherence to lifestyle changes was directly related to the degree of improvement of coronary 
atherosclerosis in patients.   
While the lifestyle and biological factors as side effects of depression are shown to 
increase the incidence of cardiovascular disease in patients, heart rate variability (HRV) is 
another indicator of heart disease.  Heart rate variability “indicates the homeostasis between the 
sympathetic and parasympathetic systems in the regulation of the heart rate and involves several 
cholinergic and monoaminergic neurotransmitters” including acetylcholine, serotonin (5‐HT), 
and dopamine—all key neurotransmitters in mood disorders and important indicators for the 
progression of myocardial infarction (Sparks et al., 1992; Chauvet-Gélinier et al., 2013).  
Moreover, depression also adversely affects heart rate variability in patients.  Research has 
shown that subjects with depression are at an increased risk of sudden postinfarction death due to 
lowered heart rate variability (Chauvet-Gélinier et al., 2013).  Thus, “decreased heart rate 
variability exposes patients with simultaneous coronary artery disease and major depression to 
ventricular arrhythmia and excess mortality” (Chauvet-Gélinier et al., 2013). 
Cardiovascular Disease, Depression, and Inflammation 
According to Chauvet-Gélinier et al. (2013), the comorbid state of depression and 
cardiovascular disease increases inflammation and oxidative stress in patients.  Research has 
shown strong evidence suggesting that “increased concentrations of blood markers of 
inflammation (interleukin-1, interleukin-6, tumor necrosis factor-alpha) have been found in both 
depression and heart disease” (Chauvet-Gélinier et al., 2013).  Additionally, a simultaneous 
   17 
 
decrease in serum concentrations of omega-3 polyunsaturated fatty acids that hold anti-
inflammatory properties has also been noticed in patients experiencing both depression and 
cardiovascular disease (Chauvet-Gélinier et al., 2013).  Moreover, psychosomatic research has 
frequently noted the strong association between inflammatory markers, oxidative stress, and 
mood disorders in subjects.  Most psychiatric disorders increase membrane lipid peroxidation 
mediated by reactive oxygen species (ROS) in patients (Chauvet-Gélinier et al., 2013).  These 
reactive oxygen species are damaging to the body and “may be ischaemic, inflammatory, or 
caused by psychological stress due to depression” (Chauvet-Gélinier et al., 2013.   
Another frequent association in the comorbid state of cardiovascular disease and mood 
disorders is a hyperactivation of the hypothalamic-pituitary-adrenal (HPA) axis.  Depression is 
considered a major stressor to the body and thus, the HPA axis in patients with depression 
becomes strongly activated (Chauvet-Gélinier et al, 2013).  As a result of HPA activation, 
elevated levels of serum cortisol urinary derivatives can be seen in depressed patients, which is 
the body’s attempt to sustain the disrupted homeostasis.  Hypercortisolemia “could induce 
glucose and lipid metabolism, leading to increased amounts of visceral fat and insulin resistance, 
both of which contribute to the development of metabolic syndrome through the activation of 
proinflammatory mediators” (Chauvet-Gélinier et al., 2013).  Chauvet-Gélinier et al. (2013), 
suggest that a disruption in the HPA axis as a result of depression could increase atherosclerosis 
in patients, thereby increasing the risk of the comorbidity of coronary heart disease. 
Various forms of arthritis also have shown to increase the risk of developing 
cardiovascular disease due to the increased circulating inflammatory compounds.  In particular, 
patients with “rheumatoid arthritis (RA) suffer cardiovascular events 1.5 - 2 fold greater than the 
general population, and cardiovascular (CV) events are the leading cause of death in patients 
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with RA,”  A more recent study showed that women with rheumatoid arthritis have a two-to-
three fold increase in myocardial infarction with or without prior coronary risk factors (Blum & 
Adawi, 2019).  Blum and Adawi (2019) strongly suggest that increased systemic inflammation is 
the main culprit in the heightened risk for cardiovascular disease in patients with RA. This is also 
considered responsible for the increased risk of cardiovascular disease in patients with poor 
dental hygiene, pneumonia, surgery, and those suffering from depression.  Additionally, patients 
with RA have been shown to have a greater risk of developing both anxiety and depression (Li, 
Chou, Chen, Lu, & Chang 2019).  According to Li et al. (2019), after examining 113 patients 
with RA compared to 42 healthy controls, those with RA had significantly higher levels of 
“serum proinflammatory cytokine levels, including interleukin (IL)-1[beta], IL-6, IL-17 and 
tumor necrosis factor-alpha (TNF-[alpha])…as were the mean anxiety and depression subscale 
scores.”  From this research, Chaddha et al. (2016) urge health professions and the public to 
acknowledge mental illness as a priority in the medical community.  They encourage further 
research on the association between depression and cardiac health, as well as to discover new 
measures for the prevention and treatment of mental and cardiovascular disease.   
Chauvet-Gélinier et al. (2013) also describe a genetic association between psychic 
disorders and cardiovascular disease.  Recent research investigating the similarity between 
depression and cardiovascular disease has found that patients with both health conditions have 
shorter telomeres, which are “genetic markers of oxidative stress that trigger cell death when the 
length reaches a critical threshold” (Chauvet-Gélinier et al., 2013).  It has been shown that the 
length of telomeres, when measured in circulating leukocytes, becomes reduced in both 
depression and coronary artery disease “illustrating in both cases the impact of oxidative stress at 
the initial level of genetic machinery” (Chauvet-Gélinier et al., 2013).  Additionally, recent 
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research highlights a disturbance in the synthesis of cardiac protective anti-inflammatory omega-
3 fatty acids due to an impairment in this metabolic pathway in depressed and cardiac patients 
(Chauvet-Gélinier et al., 2013).  Research also presents the health benefits of omega-3 fatty acids 
especially in their ability to reduce the “risk of primary cardiac arrest/sudden cardiac death, 
presumably owing to their antiarrhythmic properties.  A notable depletion of red blood cell 
membrane omega-3 fatty acids has been reported in major depression.”   Also, “a decreased 
omega-3 fraction in cholesterol esters and an increased arachidonic acid (omega-6)–
eicosapentaenoic acid (omega-3) ratio in cholesterol esters and phospholipids of major depressed 
subjects compared with minor depressed subjects and healthy controls has been found” (Severus, 
Ahrens & Stoll, 1999).  Furthermore, the mechanisms by which omega-3 fatty acids lower 
cardiac risk factors include a reduced ventricular arrhythmia, thrombosis, triglycerides, 
atherosclerotic plaque, inflammation and hypertension, and endothelial relaxation (Parletta et al., 
2016).  According to Parletta et al. (2016), cardiovascular disease is 30% higher in people with 
mental illness comparing to the general population.  Likewise, “erythrocyte docosahexaenoic 
acid (DHA) plus eicosapentaenoic acid (EPA) (omega-3 index) 4% is a marker for increased 
mortality risk from CVD while 48% is protective.  Meanwhile, “omega-3 polyunsaturated fatty 
acids are also important for brain function and may ameliorate symptoms of mental illness” 
(Parletta et al., 2016).  Inflammation has been proposed as a possible mediating role for 
comorbid physical and mental illness and may be one of the mechanisms by which omega-3 
polyunsaturated fatty acids exert their effects.  Additionally, the anti-inflammatory properties of 
eicosanoids that are produced by eicosapentaenoic acid are capable of counteracting the 
inflammatory properties of eicosanoids which are produced by arachidonic acid from the omega-
6 polyunsaturated fatty acids.   Researchers Parletta et al. (2016) recognize this as a concern in 
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“Western societies that have increased the intake of n-6 PUFA via vegetable oils and processed 
foods while decreasing intake[s] of n-3 PUFA from nuts, seeds, dark leafy vegetables, and fatty 
fish.”  A more severe depressive state has also been associated with a decreased red blood cell 
content of omega-3 fatty acids as well as a reduced intake of polyunsaturated lipids as compared 
to those with less severe depressive symptoms (Severus et al., 1999).  In further support of these 
findings, a group of Canadian researchers investigated the levels of omega-3 polyunsaturated 
fatty acids in subjects who had undergone an acute myocardial infarction and who were also 
suffering from major depression.  These subjects were found to have significantly lower levels of 
omega-3 polyunsaturated fatty acids and omega-3 indexes at 4.46% compared to those without 
depression at 5.05% (Parletta et al., 2016).   
The association between depression, cardiovascular disease, and omega-3 fatty acids 
centers on research strongly suggesting that depressed patients have lower heart rate variability 
(a risk factor for sudden cardiac death) than the general population (Severus et al., 1999).  
Supplementation with fish oils has shown to increase heart rate variability in these patients, 
thereby reducing their risk for depression and sudden cardiac death (Severus et al., 1999).  
Further research investigating the genetic influences of lipid metabolism, depression, and cardiac 
health is encouraged.  Meanwhile, a study by McCaffery et al. (2009) found a genetic 
vulnerability in 977 subjects with cardiopathy.  This subject population was found to have a 
“single nucleotide polymorphism in the gene coding for Willebrand factor in the onset of 
depression secondary to heart disease” (Chauvet-Gélinier et al., 2013).  Thus, the 
pathophysiological and genetic link between depression and cardiopathy should be further 
investigated. 
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Evidence also suggests a sympathetic hyperactivity and disturbance in platelet reactivity 
in comorbid depression and cardiovascular disease.  According to Chauvet-Gélinier et al. (2013), 
studies have shown increased levels of noradrenaline in patients with depression, as well as 
increased heart rates in these patients.  Moreover, “this excessive stimulation of the sympathetic 
system develops and aggravates coronary artery disease via a double deleterious effect on heart 
function itself and on platelet aggregation, which is diminished” (Chauvet-Gélinier et al., 2013).  
Additionally, platelet hyperactivation in depression may lead to an increased risk of 
cardiovascular disease.  Platelets contain serotonin receptors that play a role “in both hemostasis 
and coronary vasoconstriction via this monoamine,” which could exacerbate coronary disease by 
promoting ischaemic mechanisms (Chauvet-Gélinier et al., 2013).  One theory on the 
relationship between depression and cardiovascular disease proposes a common underlying 
pathophysiological process, particularly involving psychosocial stress in which serotonin is 
involved (Steiner, 2011).  Stress creates a pro-inflammatory cytokine response with the 
inflammatory molecules Interleukin-1, tumor necrosis factor-alpha, and Interferon-c (Steiner, 
2011).  According to Steiner (2011), “these cytokines act as mediators of the behavioral 
neuroendocrine (HPA axis hyperactivity) and neurochemical (reduction in 5-HT levels by 
lowering the availability of its precursor tryptophan) features of depression. These same pro-
inflammatory cytokines disrupt 5-HT levels not only in the central nervous system but also in the 
periphery, causing platelet aggregation, which leads to arteriosclerosis.”  While a reduction of 
serotonin results in platelet aggravation and thus an increased risk for CVD, the simultaneous 
effects for an increased risk of depression are also evident.   
It is well-documented that the neurotransmitter serotonin plays a vital role in the 
behaviors disrupted in depression, including mood, sleep and appetite.  It is suggested that an 
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imbalance between the ratio of 5-HT1A and 5-HT2A receptors may underlie depressive 
disorders (Steiner, 2011).  Further, serotonin, one of the main neurotransmitters contributing to 
mood, converts to melatonin from tryptophan.  Peuhkuri, Sihvola, and Korpela (2012) discuss 
the neurohormone melatonin, which is “secreted predominantly at night and is important in 
conveying the daily cycle of light and darkness to the body, thus regulating circadian rhythms 
and helping us to fall and stay asleep.”  It is known that the pineal gland in the brain contains 
high levels of both omega-6 and omega-3 polyunsaturated fatty acids, especially arachidonic 
acid and docosahexaenoic acid (DHA).  According to Peuhkuri et al. (2016), evidence shows that 
the synthesis of fatty acids has an effect on melatonin production.  In one study, rodents who 
were fed a diet deficient in omega-3 fatty acids had a reduced synthetization of night-time 
melatonin.  However, with DHA supplementation, levels of melatonin returned to normal.  This 
association again reiterates the relationship between omega-3 fatty acids, mental, and cardiac 
health.  One key element of melatonin production is that it is synthesized from tryptophan 
(tryptophan > serotonin > melatonin), an essential dietary amino acid.  Thus, research has shown 
that nutritional factors, including the dietary intake of vegetables, caffeine, vitamins, and 
minerals, has the potential to modify melatonin production.  Dietary influences on melatonin 
production still have less of an impact than light, which is the “most dominant synchronizer of 
melatonin production” (Peuhkuri et al., 2016).  Hence, serotonin has shown to be one key factor 
in the progression of comorbid depression and cardiovascular disease and additional research 
should be conducted to confirm these findings.   
Research further suggests an association between the circadian rhythm, depression, and 
heart disease.  According to Chauvet-Gélinier et al. (2013), the scientific research community 
has recently shown interest in rhythms in mood disorders, particularly the sleep cycle and 
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depression.  Evidence shows that people who have depression usually experience greater sadness 
during the morning hours and feel better as the evening arises.  The common expression of “the 
morning blues” reflects this intriguing phenomenon.  Chauvet-Gélinier et al. (2013) state that 
“alterations in the secretions of biochemical mediators (cortisol, thyroid-stimulating, melatonin, 
etc.)” can be applied to the circadian rhythm and depression.  Moreover, a similar rhythmic 
phenomenon can be seen with both depression and heart disease.   Studies have shown that 
humans have a genetic internal clock that also applies to a circadian aortic expression of the 
heart.   According to Chauvet-Gélinier et al. (2013), while it is probably impossible to “establish 
absolute links between cardiovascular disease and depression via a dysfunctioning circadian 
system, it is well known that circadian desynchronization leads to both affective disorders and 
cardiac complications.”  Chauvet-Gélinier et al. (2013) note that further investigation linking 
depression, cardiovascular disease, and a genetic connection to the circadian system should be 
encouraged.   
Researchers Mezick, Hall, and Matthews (2010) also discuss the key associations 
between sleep, depression, and cardiovascular disease.  In their literature, Mezick et al., (2010) 
state that approximately 50% to 90% of depressed patients complain of sleep disturbance as 
sleep and depression are highly related conditions.  Mezick et al. (2010) located eight 
longitudinal studies examining the relationship between sleep and depression, and cardiovascular 
disease as the outcome measurement.  The large-scale studies were comprised of middle-aged 
and older-aged community-dwelling adults.  The study duration was between 3 and 12 years.  
Subjects were given questionnaires to assess depressed mood, except for one study that asked 
only one question about depressed mood.  Exclusion criteria included subjects with baseline 
cardiovascular disease, with the exception of one study that accounted for baseline disease and 
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cardiovascular health (Mezick et al., 2010).  Results of their meta-analysis concluded that “six of 
the eight studies reported significant associations among components of poor sleep continuity 
and CVD, after adjusting for depression, whereas two did not.”  Four of the studies assessed 
found that depression or some other form of psychological distress predicted cardiovascular 
disease in patients, regardless of sleep continuity.  Moreover, Mezick et al. (2010) concluded that 
“most of the extant literature suggests that both poor sleep continuity and depression are 
independent risk factors for CVD, although there is some variation in individual study results.”  
Thus, sleep and any disruption in the circadian rhythm have shown an association with 
depression and CVD.   
Genes have also been shown to play a role in the circadian rhythm, depression, and 
cardiovascular disease.  According to Mezick et al. (2010), some evidence proposes that the 
covariation among sleep parameters, depressive symptoms, cardiovascular disease, and diabetes 
may be partially due to genetic influences. A study examining twins showed that common 
genetics significantly influenced the phenotypic correlations between depressive symptoms and 
problems with sleep in children.  Common genes in twins were also shown to play a major role 
in the physical manifestation of depressive symptoms and coronary artery disease (Mezick et al., 
2010).  Despite these findings, there is a small number of studies investigating the effects of 
sleep on comorbid depression and cardiovascular disease through the mechanism of a shared 
genetic vulnerability.  An interesting theory on genes implicated in sleep regulation has also been 
postulated.   According to Mezick et al. (2010), “disruptions of the core CLOCK genes that 
regulate endogenous circadian rhythmicity are linked to perturbations in glucose metabolism, 
adipocyte function, and vascular function, and others have theorized that clock genes may be 
implicated in the development of mood disorders.”  Circadian CLOCK genes are “any of a 
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number of genes that interact with each other to make up an auto-regulatory feedback loop, in 
which its activation and repression cycle takes about one day.  CLOCK genes are components of 
the circadian clock comparable to the cogwheels of a mechanical watch. They interact with each 
other in an intricate manner generating oscillations of gene expression.” (Albrecht & Ripperger, 
2008).  It is also believed that genetic variation may be responsible for biobehavioral pathways 
that increase the susceptibility to inflammation, HPA axis disruption, and an imbalance of the 
autonomic system—all contributing to the interrelatedness of sleep disruption, depression, as 
well as cardiometabolic disease in the patient (Mezick et al., 2010).  However, in order to further 
establish this link, research is needed examining whether depression or cardiovascular disease, or 
their comorbid state, increases the propensity for sleep disturbance, and vice-versa.   
Finally, Chauvet-Gélinier et al. (2013) provide readers with clear and thorough 
explanations of the various research associations between affective disorders, particularly 
depression and coronary heart disease.  From their discussion, the bidirectional relationship 
between depression and cardiovascular disease is described via fundamental multidimensional 
processes including behavior and psychological features, heart rate variability, inflammation, 
oxidative stress and activation of the HPA axis, the impact of stress, sympathetic hyperactivity 
and disturbances in platelet activity, and genetic markers of vulnerability to both depression and 
cardiovascular disease, as well as how the circadian system is related.  Additional research is 
needed to better understand the association between genetic variations and the circadian system 
in relation to depression and coronary artery disease.   
One of the earlier studies investigating the association between depression and heart 
disease by Ford et al. (1998) aimed to determine if clinical depression is an independent risk 
factor for incident coronary artery disease.  Ford et al. (1998) used data from the John Hopkins 
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Precursors Study to determine such a link.  The John Hopkins Precursor Study was a prospective 
observational study of 1190 male medical students enrolled in between 1948 and 1964.  These 
subjects continued follow-up throughout medical school and during the mean 37–year follow-up 
period.  Researchers collected information on family history, health behaviors, and clinical 
depression (Ford et al., 1998).  Ford et al. (1998) emphasized that “depression requires that a 
number of symptoms be present simultaneously for several weeks” and argue that, unlike other 
studies, the John Hopkins Precursor Study “has collected data on episodes of clinical depression, 
coronary artery disease risk factors, and coronary artery disease for more than 35 years and 
provides a unique opportunity to determine if individuals who have has an episode of clinical 
depression are at increased risk for the development of coronary artery disease.”  Results of the 
John Hopkins Precursor study indicated that one hundred thirty-two men reported symptoms of 
depression during the study follow-up period.  The average age of the first episode of depressive 
symptoms was 40 years, while a greater number of subjects who reported depression during 
follow-up were older (27 vs. 26, P=.03) at completion of medical school.  Additionally, of the 
depressed subjects, 23% reported not seeking medical treatment for clinical depression, 33% 
reported the use of antidepressant medications, and 44% of depressed subjects reported seeking 
psychotherapy with or without the use of benzodiazepines or other sedative drugs (Ford et al., 
1998).  The risk factors for cardiovascular disease were reported through “exercise, serum 
cholesterol levels, smoking, blood pressure, diabetes, and history of parental myocardial 
infarction” and were assessed during medical school using questionnaires, examinations, and 
blood tests (Ford et al., 1998).  Annual questionnaires, National Death Index searches, medical 
records, death certificates, and autopsy reports were used to assess the status of subjects.  At the 
conclusion of the study, investigators used collected data to determine that “clinical depression 
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was associated with an almost 2-fold increased risk for subsequent coronary heart disease” (Ford 
et al., 1998).  After adjusting for body mass index, family history of premature parental 
myocardial infarction, baseline serum cholesterol level, and time-dependent report of 
hyperlipidemia required treatment, the increased risk of coronary artery disease in these 
depressed subjects remained statistically significant (relative risk (RR), 1.7; 95% confidence 
interval [CI], 1.0-2.9) (Ford et al., 1998). 
Limitations of the John Hopkins Precursor Study include aspects of the study population.  
Approximately 98% of the subjects were white males; an obvious lack of racial diversity 
interferes with the accuracy of applying these study results to the general population comprised 
of diverse ethnicities.  Furthermore, the study population only included male subjects.  Thus, 
results of the study cannot be applied to the female population.  Another important limitation to 
consider is the highly educated study populous.  Medical school students are more informed on 
the adverse health circumstances of negative lifestyle habits, including unhealthy diets, smoking, 
and a lack of physical exercise than the general population.  Moreover, informed subjects are 
more aware of the symptoms and potential causes of depression and cardiovascular disease, 
thereby more likely to engage in activities and strategies for disease prevention.  Future research 
should control for intervening variables that may affect the relationship between the variables 
being studied through increased randomization, restriction, and matching prior to the execution 
of the study.  Additionally, if potential intervening variables exist following data collection, 
regression models can be used to adjust for them so that the true nature of the correlations 
between variables can be presented.   
In order to quantify the impact of depression on the development of coronary heart 
disease in initially healthy subjects, Rugulies (2002) conducted a systematic review of several 
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cohort studies discussing this association.  Rugulies (2002) used the search engines MEDLINE, 
PSYCHINFO, bibliographies, expert consultations, and personal reference files for studies on 
depression and cardiovascular disease in healthy populations.  A total of eleven studies met the 
inclusion and exclusion criteria set forth by Rugulies (2002) which consisted of prospective 
cohort studies on initially healthy subjects with depression as the predictor and coronary heart 
disease as the outcome measurement.  Types of exposure included unipolar clinical depression 
and depressive mood—both terms refer to “depression.”  Eligible outcomes of depression and 
coronary artery disease included fatal and nonfatal myocardial infarction, coronary death, and 
cardiac death.   Certain exclusion criteria were also listed: case-control and cross-sectional 
studies, bipolar disorders and the outcome of angina pectoris (Rugulies, 2002).  Results of 
Rugulies’ (2002) review indicated that in 7 of the 11 studies, “depression was associated with a 
significant increased risk of coronary heart disease,” including all 3 of the studies that measured 
for clinical depression with relative risks (RRs) ranging from 1.50 (95% CI=1.02-2.19) to 4.16 
(1.49-11.62) (Rugulies, 2002).  Moreover, the other 4 studies showed a positive association 
between depression and cardiovascular disease, however, findings were inconsistent.   
The limitations of Rugulies’ (2002) meta-analytic review included publication bias; all 
studies in the review were published, therefore research linking clinical depression to 
cardiovascular disease that may have been unpublished were not accounted for.  Additionally, 
Rugulies (2002) acknowledges his use of very strict inclusion and exclusion criteria for his 
review.  This is especially true of his exclusion of research pertaining to angina pectoris for 
eligible outcomes since angina pectoris is a significant manifestation of coronary heart disease.  
Rugulies (2002) was also unable to investigate the dose-response relationship between 
depression and cardiovascular disease in his review and clinical depression being a strong 
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predictor of heart disease points to a likely dose-response relationship.  Finally, none of the 
studies assessed the effects of mild symptoms of depression on cardiovascular disease—a topic 
for further research. 
Various cardiovascular health metrics have been assessed for their correlation to 
depression among adults in the United States.  According to Zhang, Jackson, Merritt, Gillespie 
and Yang (2019), while death rates over the past several decades have declined, death from 
cardiovascular disease remains the leading cause of death in the United States and resulted in 
30.8% (or 800,937) of all deaths in 2013 (Zhang et al.,2019).  Zhang et al. (2019) state the 
following:  
“The total direct medical costs of [cardiovascular disease] are projected to increase to 
$918 billion by 2030.  A substantial body of evidence demonstrated that individuals with 
favorable levels of major [cardiovascular] risk factors experienced a significant reduced 
risk of cardiovascular incidence and mortality.”   
The American Heart Association recognizes seven cardiovascular health metrics, consisting of 
four health behaviors and three health factors.  The four health behaviors include body mass 
index, smoking, physical activity, and dietary intake.  The three health factors include total 
cholesterol, blood pressure, and fasting glucose (Zhang et al., 2019).  The American Heart 
Association asserts that all seven cardiovascular health factors are modifiable and can be 
categorized into three levels: poor, intermediate, and ideal health. 
Moreover, Zhang et al. (2019) recognize depression as one of the most common chronic 
conditions in general practice, affecting 1 in 10 patients and over 311 million people worldwide 
(Zhang et al., 2019).  Zhang et al. (2019) state that depression is an independent risk factor for 
“increased morbidity and mortality, lower functional status, and [worsens] quality of life as well 
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as [increases] costs.”  In a survey of 245,404 adults from over 60 countries, comorbid depression 
was found to be worse for health outcomes of patients than those suffering from asthma, 
diabetes, arthritis, or cardiovascular disease alone (Zhang et al., 2019).  Thus, in their article 
Zhang et al. (2019) investigated the relationship between different health metrics of 
cardiovascular as set forth by the American Heart Association, and clinical depression using 
nationally representative samples.   
Researchers Zhang et al. (2019) used data from the National Health and Nutrition 
Examination Survey (NHANES) that ran from 2007-2014 to find correlations between 
depression and cardiovascular disease.  The NHANES study “uses a complex, stratified, 
multistage probability cluster sampling, cross-sectioning design to collect health and nutritional 
data from a representative sample of the noninstitutionalized U.S. population” (Zhang et al., 
2019).  A total of 14,561 participants aged 20 years or older met the inclusion and exclusion 
criteria set forth by Zhang et al. (2019).  All participants completed a reliable 24-hour dietary 
recall.  Pregnant women, subjects with missing cardiovascular health metrics scores, depression 
scores, BMI scores, and those with BMIs of less than 18.5 kg/m2 were excluded from the study.  
Subjects with a history of cardiovascular disease (myocardial infarction, congestive heart failure, 
and stroke) and participants with cancer were also excluded from the study (Zhang et al., 2019).  
Zhang et al. (2019) used the Healthy Eating Index 2010 (HEI-2010) scores to assess dietary 
patterns of subjects.  The HEI-2010 is based on a 12-component index for total fruit, whole fruit, 
total vegetables, grains and beans, whole grains, dairy, total protein foods, seafood and plant 
protein, fatty acid, refined grains, sodium, and empty calories.  Possible scores ranged from 0 to 
100—higher scores indicating a healthier diet (Zhang et al., 2019).   
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Symptoms of depression were gathered using the Patient Health Questionnaire (PHQ-9), 
“a validated nine-item screening instrument that asks about the frequency of depressive 
symptoms over the past 2 weeks” with “not at all,” “several days,” “more than half the day,” and 
“nearly every day” as possible responses (Zhang et al., 2019).   Additionally, the NHANES was 
analyzed for depressive symptoms with adjustments for age, gender, race and ethnicity, 
education, and alcohol use.  Results of Zhang et al.’s (2019) study concluded that there is a 
strong and graded association between mild, moderate, and severe depressive symptoms and 
cardiovascular health metrics among U.S. adults.  From this research, Zhang et al. (2019) also 
found that participants with fewer cardiovascular health metrics had an increased risk for 
experiencing symptoms of depression and these results were consistent among various 
subgroups.   
Furthermore, Li et al. (2015) investigated the relationship between cardiovascular health 
(CVH) and depression among 6,851 men, 20 years or older, living in the Tangshan City of 
China.  Researchers used seven CVH metrics including smoking, body mass index, dietary 
intake, physical activity, blood pressure, total cholesterol and fasting blood glucose to assess 
ideal heart health.  Participants were measured for depression using the Epidemiologic Studies 
Depression Scale (CES-D) and any score of 16 or above was indicative of depressive status (Li 
et al., 2015).  Li et al., (2015) analyzed the relationship between cardiovascular health metrics 
and depression using logistic regression.  Of the 6851 subjects in the study, 7.7% were found to 
suffer from depression.  After adjusting data for the potential of confounding variables, Li et al. 
(2015) found that “men in the highest quartile of ideal CVH metric summary score had a reduced 
likelihood of having depression compared to those in the lowest quartile.”  Thus, Li et al. (2015) 
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suggest that improved CVH status is associated with a lower risk of depression in Chinese men 
over the age of 20.  
A study by Espana-Romero et al., (2013) also investigated the relationship between ideal 
cardiovascular health and the likelihood of depressive symptoms.  A total of 5110 participants 
were gathered from the Aerobics Center Longitudinal Study, which progressed between 1987 
and 1998.  Researchers included subjects who did not present with any mental disorder/condition 
at baseline.  Espana-Romero et al. (2013) considered various ideal cardiovascular health 
behaviors which included never smoking, body mass index <25g/m2, physical activity, and 
appropriate diet consistent with guideline recommendations.  Blood pressure (<120/80mm Hg), 
total cholesterol (<200mg/dL) and fasting blood glucose (<100mg/dL) were measured at baseline 
for all participants.  At the conclusion of the study, Espana-Romero et al. (2013) found that of 
the 5110 participants, 641 reported depressive symptoms indicated using the 10-item Center for 
Epidemiologic Studies Depression Scale in 1990, 1995, or 1999.  Results of the study suggest 
that ideal cardiovascular factors pose an inverse relationship with symptoms of depression 
(Espana-Romero et al., 2013).   
According to Moussavi, Chatterji, Verdes, Tandon, Patel, and Ustun (2007), depression is 
one of the leading causes of disease worldwide.  Additionally, “depression produces the greatest 
decrement in health compared with the chronic diseases’ angina, arthritis, asthma, and diabetes. 
The comorbid state of depression incrementally worsens health compared with depression alone, 
with any of the chronic diseases alone, and with any combination of chronic diseases without 
depression (Moussavi et al., 2007).  Therefore, Moussavi et al. (2007) urge the public to address 
depression as a worldwide health crisis and a public-health priority. 
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Researchers Hare et al. (2014) also confirm findings that patients with cardiovascular 
disease have higher rates of depression than the general population.  Also, Hare et al. (2014) 
propose that people who suffer from depression are more likely to develop cardiovascular 
disease and have an increased risk of all-cause mortality as compared to the rest of the 
population.  The relationship between depression and cardiovascular disease is graded—the more 
depressed an individual, the more severe the cardiovascular disease.  The detection of depression 
in cardiovascular disease patients is important.  According to Hare et al. (2019), “depression is 
arguably the single most important driver of quality of life and therefore needs to be prevented 
and appropriately managed if it is subsequently detected in CVD patients.”  It goes without 
refute that the lower the quality-of-life of an individual, the increased risk for depression, and 
thus the increased risk for cardiovascular disease—especially since the relationship between 
depression and cardiovascular disease has become well-established. 
 
  





A comprehensive review of the literature on depression, cardiovascular disease, non-
pharmacotherapy, and psychotherapy was conducted.   
Procedures 
Search procedure. A careful review of the literature related to non-pharmacotherapy, 
depression, and cardiovascular disease was conducted.  The review highlighted the following 
topics: (a) psychotherapy, (b) depression, (c) cardiovascular disease, (d) major depressive 
disorder, (e) non-pharmacotherapy, (f) cognitive behavior therapy, (g) meditation, (h) 
acupuncture, (i) physical exercise, and (j) mindfulness therapy. 
Libraries used. There was one library used for the search for sources for this project.  The 
Wahlstrom Library at the University of Bridgeport was used for this review. 
Search engines and databases used.  The following databases were used to search for the 
sources for this review: PubMed, EBSCOhost, Google, and Google Scholar. 
Search terms. Several search terms were used to identify sources for this review.  The 
search terms included (a) non-pharmacotherapy, (b) depression, (c) cardiovascular disease, (d) 
major depressive disorder, (e) cognitive behavior therapy, (f) psychotherapy, (g) meditation, (h) 
acupuncture, (i) physical exercise, and (j) mindfulness therapy. 
Age of the sources and significant literature was reviewed.  Sources from the year 1980 
and above have been considered for inclusion in the review of the literature.
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Inclusion criteria. There were four inclusion criteria.  Inclusion criteria included (a) 
literature published since 1980; (b) English-language text; (c) peer-reviewed articles; and (d) 
Websites relating to non-pharmacotherapy, psychotherapy, depression, and cardiovascular 
disease.   
Exclusion criteria. There were four exclusion criteria.  The exclusion criteria included (a) 
literature published before 1980; (b) text not published in English; (c) articles not peer-reviewed; 
and (d) websites unrelated to non-pharmacotherapy, psychotherapy, depression, and 
cardiovascular disease.  




The predominance of research investigating the effects of different forms of non-
pharmacotherapy, particularly psychotherapy on mental health and depression, point to a 
reduction in depressive symptoms with mental and emotional counseling.  Psychotherapy is also 
referred to as talk therapy, counseling, psychosocial therapy or, simply, therapy (Mayo Clinic, 
2016).  In a meta-analytic review of research, Kolovos, Kleiboer, and Cuijpers (2016) aimed to 
discover the effects of psychotherapy on both reducing symptom severity in depressed patients, 
as well as the effects of psychotherapy on quality-of-life (QoL), and mental and physical health 
as related to QoL.  According to Kolovos et al. (2016), “quality-of-life (QoL) is a broad concept 
that comprises a range of life domains of the individual, such as social relationships, physical 
abilities, mental health functioning, role functioning and engagement in daily activities.  Deficits 
in all these domains have been identified in people experiencing depressive symptoms.”  The 
researchers assessed 44 randomized controlled clinical trials comparing subjects with depression 
who received psychotherapy treatment with controls.  Inclusion criteria consisted of subjects 
who were 18-years-or-older, research from randomized control trials comparing subjects with 
depression who received psychotherapy versus a control group where psychotherapy was not 
administered.  Only studies where subjects were diagnosed with a depressive disorder through a 
structural clinical interview were used.  Psychotherapy was defined as any intervention where the 
core element was verbal communication between the depressed subject and a therapist, or as a 
systematic psychological intervention in which the depressed participant worked independently 
on self-help measures such as with a book or website, while simultaneously receiving personal 
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support from a therapist (Kolovos et al., 2016).  Quality-of-life is defined “as any patient-
reported measure aiming to assess perceived health status, well-being or effective performance in 
daily life.  These measures could provide a global (overall) score, or separate scores for different 
domains or components.”  Kolovos et al., (2016) included studies where QoL was centered on 
the mental and physical health of subjects.  Mental health was defined as a personal satisfaction 
with the current psychological state, while the physical health component of studies was defined 
as “the perceived competence for performance and functioning in various everyday activities” 
(Kolovos et al., 2016).   
 The 44 studies that met inclusion and exclusion criteria encompassed a total of 5264 
patients, with 2907 in the intervention group who received psychotherapy and 2357 patients in 
the control group without treatment.  Of the 44 studies included in their research, 25 studies 
involved cognitive-behavioral therapy, mindfulness-based cognitive therapy, and coping with 
depression as forms of psychotherapy administered (Kolovos et al., 2016).  Furthermore, 
researchers assessed quality-of-life as “life review in five studies (14%), problem-solving 
treatment in three studies (8%), acceptance and commitment therapy in three studies (8%) and 
interpersonal psychotherapy in two studies (5%).”  The most common control condition for 
subjects was “care as usual” and this was included in 20 (45%) of the studies analyzed for data.  
Control conditions ranged from discussion groups, psycho-education, and a 20-minute 
educational video or placebo pill.  Subjects received an average of 10 treatment sessions for 
depression. 
 According to Kolovos et al. (2016), results of their study indicated that psychotherapy for 
depression, mental health, and physical health reduced symptoms of depression and increased 
quality-of-life for most subjects.  Thus, results of their study supported previous evidence 
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indicating a positive effect on depression, mental and physical well-being through 
psychotherapeutics.  Moreover, Kolovos et al. (2016) concluded that “psychotherapy for 
depression is beneficial not only for depressive symptoms but also for quality-of-life.  Overall, it 
can be concluded that psychotherapy has a positive impact on various domains of a patient’s life, 
such as mental functioning, social and work-related relationships, level of discomfort and 
engagement in everyday activities.”  Patients who engaged in psychotherapy experienced greater 
improvements in QoL compared to control conditions.  Additionally, the mental health 
component had the largest effect size when treated with psychotherapy.  The smallest effect was 
seen in the physical health component, while there was only a moderate effect size for global 
QoL.  Despite the smaller effect, physical health is an important predictor of cardiovascular 
health (Chaddha et al, 2016).   
Researchers Pinheiro, Reshetnyak, Sterling, Richman, Kern and Safford (2019) used data 
from the national Reasons for Geographic and Racial Differences in Stroke (REGARDS) cohort 
study to determine associations between baseline heart-related quality-of-life (HRQOL) and 
incident CVD events among adults with no history of stroke or heart disease.  After their analysis 
of 1766 CVD events, Pinheiro et al. (2019) found that subjects who had scores of Physical 
Component Summary (PCS) and Mental Component Summary (MCS) scores of less than 50, 
which range from 0 to 100, had a lower heart-related quality-of-life, while higher scores 
indicated better HRQOL.  To further support this, higher self-reported PCS and MCS scores 
were significantly associated with a lower risk of cardiovascular disease in patients, while lower 
scores were indicative of a higher risk for cardiovascular disease, coronary artery disease, and 
stroke (Pinheiro et al., 2019).  
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Kolovos et al. (2016) acknowledge some limitations of their study.  While there was only 
a small effect size of psychotherapy on physical health, they mention that only a few comparison 
studies were available discussing the effects of psychotherapy on physical health and they 
“lacked adequate power to detect small effect sizes.  A larger number of studies would allow [the 
interpretation] of results with more confidence.”  Further research should be conducted on the 
effects of psychotherapy on patients with depression and their physical health (defined as the 
perceived competence for performance and functioning in various everyday activities) (Kolovos 
et al., 2016).  Kolovos et al. (2016) state that QoL is inherently a subjective construct that could 
be perceived differently depending on the individual.  Thus, it becomes difficult to measure the 
exact effects of psychotherapy on global QoL.  Additionally, the research design used by 
Kolovos et al. (2016) did not allow researchers to determine causal or temporal relationships 
between QoL and symptoms of depression.  Hence, “a longitudinal design with repeated 
measurements of QoL and depressive symptoms is needed to examine whether changes in 
depressive symptoms lead to changes in QoL or vice versa” (Kolovos et al., 2016).  Kolovos et 
al. (2016) also acknowledge that their study only examined the short-term effects of 
psychotherapy on major depressive disorder, mental and physical health.  Long-term studies 
should be encouraged to determine any further effects of psychotherapy on people with 
depression.   While limitations of the study exist, psychotherapy is shown to be an effective 
treatment for people who experience both depressive symptoms and distress in their quality-of-
life. 
High rates of depressive disorders are found in primary care settings, where patients are 
receiving treatment (Nieuwsma, Trivedi, McDuffie, Kronish, Benjamin, & Williams, 2018).  
Despite the availability of extensive evidence and clinical guidelines that strongly encourage the 
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treatment of depression with both psychotherapy and pharmacotherapy, “medication is by far the 
most commonly utilized intervention in primary care settings” (Nieuwsma et al., 2018).  
However, primary care health professionals who treat patients with major depressive disorder 
continually try to integrate both psychotherapy and pharmacotherapy in treating patients for 
several beneficial reasons.  According to Nieuwsma et al. (2018), integrating both psychotherapy 
and pharmacotherapy has multiple advantages over treatment with only one-or-the-other.  “There 
are many patients who prefer psychotherapy to medication; there is a need to provide alternative 
treatments for patients who do not improve on or cannot tolerate antidepressant medication and 
there may be unique benefits from psychotherapy in terms of costs and relapse prevention” 
(Nieuwsma et al., 2018).  One of the main obstacles in providing patients with non-
pharmacotherapy for depression is the lengthy aspect of psychotherapy.  Most patients who 
engage in psychotherapy for depression are required to participate in 12 to 20 weekly 1-hour 
sessions with a therapist and “is arguably still too intensive for reliable implementation in 
primary care settings” (Nieuwsma et al., 2018).  Thus, it is important to recognize the time and 
resource constraints of traditional psychotherapies and determine whether brief psychotherapy 
sessions are as effective in relieving depression as the standard-duration psychotherapies (i.e., 
12-20 sessions).  In their article Nieuwsma et al. (2018) investigate whether brief sessions of 
psychotherapy of 8 or fewer sessions are efficacious for the treatment of depression.  The authors 
conducted a systematic review of research investigating the effects of lengthy versus brief 
psychotherapy sessions for major depressive disorder.  Particular attention was devoted to the 
“training received by providers delivering brief psychotherapies and the reporting of clinical 
outcomes beyond depression severity” (Nieuwsma et al., 2018).  It is important to reiterate the 
strong positive bidirectional correlation between depression and CVD.  Therefore, by reducing 
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the symptoms of depression in patients through short or long-term psychotherapy, we can further 
reduce the risk of cardiovascular disease.  
After conducting a complex systematic review of the research available on MEDLINE 
(PubMed), Embase, and PsycINFO investigating standard versus brief psychotherapy for 
depression, a total of 2 systematic reviews and 15 randomized control trials met both inclusion 
and exclusion criteria (Nieuwsma et al., 2018).  A total of 1716 patients encompassed all 17 
research articles.   Adults diagnosed with major depressive disorder (MDD), dysthymic disorder, 
or subthreshold (minor) depression in acute-phase treatment were included in the review.  
Studies that included subjects being treated with “cognitive-behavioral therapy (CBT) (including 
cognitive therapy and behavior therapy), interpersonal therapy (IPT), problem-solving therapy 
(PST), mindfulness-based cognitive therapy (MBCT), cognitive behavioral analysis system of 
psychotherapy (CBASP), dialectical behavioral therapy (DBT), functional analytic 
psychotherapy (FAP), acceptance and commitment therapy (ACT), or short-term psychodynamic 
therapy with ≤ 8 planned sessions were included in the review” (Nieuwsma et al., 2018).  
Research where subjects were treated with antidepressant medication (if the intervention was 
psychotherapy plus antidepressant) were included.  Inclusion criteria for settings involved 
outpatient general medical or general mental health clinics.  All included research measured 
depressive symptoms using a validated instrument which reported patient status at ≥ 6 weeks 
following randomization.  Furthermore, subjects with treatment-resistant depression, postpartum 
depression, premenstrual dysphoric disorder, bipolar disorder, seasonal affective disorder, or 
double depression (i.e., MDD and dysthymia) were excluded from the review (Nieuwsma et al., 
2018).   Studies where subjects received the following interventions for depression were 
excluded: generic counseling, life review therapy, psycho-educational therapy, supportive 
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therapy, bibliotherapy, or Internet-based psychotherapies.  Any study conducted outside of North 
America, Western Europe, New Zealand, or Australia were also excluded (Nieuwsma et al., 
2018).  There were no exclusion criteria for outcomes of brief psychotherapy.    
Many of the studies used in Nieuwsma et al.’s (2018) review did not use a single type of 
instrument to measure depression severity.  Therefore, Nieuwsma et al. (2018) calculated effect 
sizes for each study by “subtracting (at post-test) the average score of the control group from the 
average score of the experimental group and dividing the result by the pooled standard deviations 
(SDs) of the experimental and control groups.”  After assessing results of their meta-analysis, 
Nieuwsma et al., (2018) found that patients who engaged in 6 to 8 sessions of psychotherapy had 
reduced symptoms of depression (ES −0.42, 95% CI −0.74 to −0.10) as compared to participants 
receiving a control treatment.  However, the effects of treatment were significantly different 
across all studies (Cochran Q=13.74, p=0.03, I2=56%).  A limitation of the analysis of brief 
cognitive-behavioral therapy for depression was the small number of studies available at only 
6—making it difficult for Nieuwsma et al. (2018) to detect publication bias.  While only six 
studies using brief cognitive-behavioral therapy was a limiting factor, after correcting for 
confounding variables, Nieuwsma et al. (2018) found that 6 to 8 sessions of cognitive-behavioral 
therapy was significantly more effective in relieving symptoms of depression in patients 
compared to controls (ES −0.50, 95% CI −0.91 to −0.09).  Furthermore, the single study 
investigating the effects of brief mindfulness-based cognitive therapy (MBCT) on depression 
“found 8 sessions of MBCT to be more efficacious than treatment as usual at reducing 
depressive symptoms at 8 weeks” (F=13.42, p=0.001) (Nieuwsma et al., 2018).  According to 
Nieuwsma et al. (2018), “effect sizes for brief psychotherapy are modest but at present appear 
comparable to those observed in trials of antidepressant medications and of standard duration 
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psychotherapies.”  Moreover, for patients with severe depression, 16 sessions of psychotherapy 
were found to be more effective in reducing symptom severity than only 8 sessions (Nieuwsma 
et al., 2018).   
There were several strengths and weaknesses of the Nieuwsma et al.’s (2018) meta-
analytic review.  The low number of available studies was a limiting factor in the strength of the 
conclusions drawn by the authors—that brief psychotherapy is as effective as standard 
psychotherapy for the treatment of depression.  Also, psychotherapy for patients was 
administered by various types of health professionals including “psychologists, graduate 
students, nurses, general practitioners, and other allied health professionals who had received 
training and supervision specific to the intervention being conducted” (Nieuwsma et al., 2018).  
However, a varied type of professional intervention offered sparse details about the training 
received by counselors to provide therapy for patients, “meaning that the degree of training 
necessary to replicate studies’ results is uncertain” (Nieuwsma et al., 2018).  Furthermore, too 
few studies investigated the effects of brief psychotherapy for the long-term (6 months or more) 
treatment of depression.  The subject population demographics were limited primarily to 
Caucasian, middle-aged females, which does not allow results to be transferable to other 
segments of the population.  Finally, according to Nieuwsma et al. (2018) “the relatively few 
studies included in this review did not allow for stratified comparisons on important variables 
such as depression severity (i.e., mild, moderate, severe), treatment setting (e.g., mental health 
clinic, primary care), or augmentation of brief psychotherapy with medication.”  While strengths 
and weaknesses of their study do exist, Nieuwsma et al. (2018) still encourage the implantation 
of brief psychotherapy along with pharmacology for the treatment of major depressive disorder 
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in primary care settings, specifically noting the added benefits of talk therapy to medication in 
the treatment of mental health disorders.  
As previously reflected in Nieuwsma et al.’s (2018) literature, another form of 
psychotherapy, cognitive behavior therapy (CBT), improves depressive symptoms in patients.  
Since depression and cardiovascular disease are strongly related, a randomized controlled trial by 
Turner, Hambridge, Baker, Bowman, and McElduff (2012) examined the influence of group 
cognitive behavior therapy versus brief intervention for depression in cardiac patients.  In their 
study, a total of 57 community-dwelling cardiac patients who had a score of >13 on the Beck 
Depression Inventory-II received a single-brief psychotherapeutic intervention for depression.  
Following their brief session of psychotherapy, these patients were later block randomized to 
either six sessions of group cognitive behavior therapy (n=25) or no further intervention (n=32).  
All patients were reassessed for depression severity at 2, 6, and 12 months using the Beck 
Depression Inventory-II and the Hospital Anxiety and Depression Scale-Anxiety (HADS-A).  
The HADS-A assesses rates of depression and anxiety symptoms (Turner et al., 2012).  Results 
of Turner et al.’s (2012) indicated significant improvements for the total group from baseline to 
12 months follow-up.  Turner et al. (2012) discovered no significant differences in cognitive 
behavior interventions or brief interventions on the BDI-II score, major rates of depression, or on 
the HADS-A score.  While there was no difference between CBT and brief intervention for 
depression in cardiac patients, overall results indicated group psychotherapy reduced symptom 
severity in depressed patients.  Furthermore, Turner et al. (2012) state that “non-response to 
depression treatment following acute myocardial infarction has been associated with increased 
cardiac morbidity.”  Therefore, cognitive behavior therapy for depressed cardiac patients is a 
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promising non-pharmaceutical intervention to prevent the progression of cardiovascular disease 
in depressed patients.   
Cognitive behavioral therapy is one of the most common forms of psychotherapy used by 
mental health professionals to treat mental and emotional disorders, particularly major depressive 
disorder (Leuzinger-Bohleber et al., 2019).  Much of the research available investigates the 
effects of psychotherapy on major depression and centers on cognitive behavioral therapy.  
Cognitive behavior therapists usually treat patients with depression through “problem analysis, 
goals, psychoeducation, rationale for treatment; behavioral activation, increasing pleasant 
activities; cognitive interventions to restructure basic assumptions, schemata; social skill 
training, problem-solving, stress management; maintenance, and relapse prevention” (Leuzinger-
Bohleber et al., 2019).  Moreover, previous studies investigating the mental health implications 
of short-term cognitive-behavior therapy have established it as an effective treatment for acute 
unipolar depression.  Additionally, short-term psychodynamic psychotherapy (PAT) was found 
equally effective compared to short term CBT and other psychotherapies (Leuzinger-Bohleber et 
al., 2019).  A more recent controlled, single-blind, multicenter, 4-arm study by Leuzinger-
Bohleber et al. (2019) was first to compare the effectiveness of long-term cognitive-behavioral 
therapy and long-term psychoanalytic therapy on chronically depressed patients and the effects 
of preferential or randomized allocation on outcomes.   
A total of 252 adult males between the ages of 21 and 60 years-of-age who were gathered 
from 4 study centers in Germany (Frankfurt, Mainz, Berlin, and Hamburg) met the inclusion and 
exclusion criteria set forth by Leuzinger-Bohleber et al. (2019).  All of these men had been 
suffering from either major depression, dysthymia, or double depression for at least 12 months or 
more.  Dysthymic disorder (DD) is defined as a mild or moderate form of chronic depression but 
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those diagnosed with dysthymia still meet the criteria for a major depressive episode or double 
depression occurring at some point in their lives (Klein, Shankman, & Rose, 2008).  Double 
depression is a complication of dysthymia in which the individual experiencing mild chronic 
depression succumbs to the full syndrome of major depressive disorder later in life, usually a 
result of not seeking treatment (WebMD, 2017).  Furthermore, only subjects with a depression 
severity score of >9 on the clinician-rated Quick Inventory of Depressive Symptoms (QIDS), and 
a score of >17 on the Beck Depression Inventory II (BDI-self-report), and those who gave 
informed consent were asked to participate.  Leuzinger-Bohleber et al. (2019) gave subjects the 
ability to choose whether to be treated with long-term cognitive-behavioral therapy or long-term 
psychoanalytic therapy, or were assigned to treatment randomly.  Patients taking antidepressant 
medication were only included in the study if they were taking the medication for at least 4 
weeks (Leuzinger-Bohleber et al., 2019).  A total of 73 psychoanalytic therapists were recruited 
to provide counseling to patients.  Psychoanalytic therapists were trained in their discipline by 
engaging in workshops centered on the empirically validated psychoanalytic manual for the 
treatment of chronic depression.  Additionally, psychoanalytic therapists were taught to “uncover 
and modify the unconscious idiosyncratic fantasies and conflicts due to developmental deficits 
and traumatizations underlying chronic depression…manifested in dreams, current object 
relationships, fantasies leading into psychic retreat) and worked through the ‘here and now’ of 
the transference relationship, aiming to change the psychic structure” of the patient (Leuzinger-
Bohleber et al., 2019).  Both psychoanalytic therapists and state-licensed cognitive-behavioral 
therapists were required to have at least three years of previous clinical practice.  Leuzinger-
Bohleber et al., (2019) refer to their research as the Long-term Psychotherapies for Chronically 
Depressed Patients (LAC) study.   
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To measure patient adherence to both psychoanalytic therapy and cognitive-behavioral 
therapy, Leuzinger-Bohleber et al., (2019) used the Comparative Psychotherapy Process Scale 
(CPPS) and analyzed randomly selected audiotapes of therapy sessions.  Audiotapes were 
assessed for type of therapy given and for interrater reliability which was satisfactorily high with 
an intraclass correlation coefficient score (ICC) of >.85.  The Beck Depression Inventory II 
(BDI) and the (clinician-rated) QIDS were used to measure the main outcomes of the study.  
Data results were presented as follows: “over the first year, the average (total) BDI declined from 
32.1 by 12.1 points and 17.2 points after 3 years.  BDI overall mean effect sizes increased from d 
¼ 1.17 after 1 year to d ¼ 1.83 after 3 years.  Full remission rates for BDI increased from 34% to 
45% after 3 years. The average QIDS-C declined by 6.4 points over the first year and by 8.5 
points over 3 years. The QIDS-C overall effect sizes increased from d ¼ 1.56 to d ¼ 2.08, and 
full remission rates rose from 39% after 1 year to 61% after 3 years” (Leuzinger-Bohleber et al., 
2019).  Thus, Leuzinger-Bohleber et al.’s (2019) study results suggest a significant reduction in 
depressive symptoms after long-term treatment with psychoanalytic and cognitive-behavioral 
therapy for patients suffering from chronic depression.  Also, patients who were treated with 
their preferred form of psychotherapy did not achieve better outcomes than patients who were 
randomly allocated to their form of treatment therapy. 
There are various weaknesses in the LAC study by Leuzinger-Bohleber et al. (2019).  
One of the main weaknesses involves the all-male study population, preventing the application of 
results to females.  The study population also included only subjects gathered from different 
locations in Germany.  Thus, cultural or ethnic variations are not accounted for in Leuzinger-
Bohleber et al.’s (2019) study and further research on the effects of long-term psychotherapies 
on chronic depression should be conducted on diverse groups.  Since two-thirds of the study 
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population had a therapeutic preference, the randomization arm for the random allocation to 
therapy was not strong enough to determine true power.  Further, the study population included 
severely ill patients considered “difficult-to-treat,” who had experiences with severe and 
cumulative childhood trauma, primarily emotional neglect, which may lead to an increased 
likelihood of relapse into depression.  Moreover, because the participants were severely ill 
patients, medication could not be stopped or modified for ethical reasons.  According to 
Leuzinger-Bohleber et al., (2019), “despite these limitations, the conclusion of this study is that 
psychoanalytic long-term psychotherapy, as well as cognitive-behavioral long-term 
psychotherapeutic treatments, help chronically depressed patients to achieve a sustained 
reduction of depressive symptoms and to substantially improve the remission rates.”  Results of 
the study indicated no significant difference between psychoanalytic therapy and cognitive-
behavioral therapy in reducing symptoms of depression.  While Leuzinger-Bohleber et al.’s 
(2019) did not investigate the relationship between depression and cardiovascular disease in 
patients, or whether patients with depression were also diagnosed with cardiovascular disease, 
previous research strongly suggesting the interrelationship between depression and CVD does 
point to the benefits of psychotherapy for both disease states.  Additionally, the significant 
improvements in the severity of depressive symptoms in patients using psychoanalytic long-term 
psychotherapy and cognitive behavior therapy again highlights the underlying bidirectional 
relationship between depression and cardiovascular disease—a decrease in depression likely 
correlates to a decreased risk for cardiovascular disease through treatment with various forms of 
psychotherapy.   
 Another randomized control trial conducted by Nakagawa et al. (2017) aimed to 
determine the effectiveness of supplementary cognitive-behavioral therapy for pharmacotherapy-
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resistant depression.  In their rationale, Nakagawa et al. (2017) allude to the difficulty in treating 
all depressed patients with pharmacotherapy, since “antidepressant medication is efficacious in 
the treatment of depression, but not all patients improve with antidepressant medication alone.”  
Additionally, “it is estimated that only a third of patients fully respond to the initial course of  
antidepressants and only a quarter to the second course.  The sizable proportion of patients who 
fail to respond to pharmacotherapy is considered to have treatment-resistant depression” 
(Nakagawa et al., 2017).  A plethora of research suggests that cognitive-behavioral therapy is 
equally effective for depression as antidepressant therapy alone and combining cognitive-
behavioral therapy and antidepressant therapy is even more effective (Nakagawa et al., 2017).  
While there is literature supporting combination therapy for the treatment of depression, there is 
a lack of research focused on combination therapy on pharmacotherapy-resistant patients 
suffering from depression and cardiovascular disease.   
 Nakagawa et al.’s (2017) research consisted of a 16-week assessor-masked randomized 
control trial with a 12-month follow-up that ran from September 2008 to December 2014.  The 
subject population included adult outpatients between the ages of 20 and 65 years who had 
pharmacotherapy-resistant depression, and were taking antidepressant medication for at least 8 
weeks.  Subjects were also evaluated for the GRID-Hamilton Depression Rating Scale, the 
Maudsley Staging Method for treatment-resistant depression and were assessed for meeting the 
DSM-IV criteria for major depressive disorder.  Only subjects with a score of ≥ 16 on the GRID-
Hamilton Depression Rating Scale, a score of ≥ 3 on the Maudsley Staging Method for 
treatment-resistant depression scale, and those who met DSM-IV criteria for major depression 
were included in the study.  A total of 80 participants seeking psychiatric specialty care were 
randomly assigned to two groups, those who would receive cognitive-behavioral therapy with 
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treatment as usual (TAU) or those who would receive TAU alone (antidepressant medication).  
The subjects were gathered from two study sites: a university teaching hospital and a psychiatric 
hospital located in Tokyo, Japan.  Additional inclusion criteria consisted of having major 
depressive disorder as explained by the DSM-IV without psychotic features explained by the 
DSM-IV-TR Axis I Disorders Patient Edition.  Exclusion criteria included any other DSM-IV 
Axis diagnosis other than major depressive disorder, manic or psychotic episodes, and alcohol or 
substance use disorder.  Any subject with any form of anti-social personality disorder, serious 
and imminent suicidal ideations, organic brain lesions, or major cognitive deficits, as well as any 
serious or unstable medical conditions were excluded from the study.  Additionally, subjects who 
have received cognitive-behavioral therapy in the past or had already attended at least 8 or more 
CBT sessions were excluded.  Finally, subjects who were unlikely to adhere to at least 8 sessions 
of cognitive-behavioral therapy for the entirety of the study period were also excluded 
(Nakagawa et al., 2017).   
 Participants in the CBT group were offered sixteen individual sessions that lasted 50 
minutes that were scheduled weekly.  Some subjects were offered an additional four sessions if 
“deemed clinically appropriate by the therapist” (Nakagawa et al., 2017).  The therapists that 
counseled patients with cognitive-behavioral therapy followed guidelines and procedures set 
forth by the CBT Manual for Depression, which includes adaptations for Japanese culture and 
certain characteristics of Japanese patients, including “their emphasis on interpersonal 
relationships and consideration of family as an essential part of treatment” (Nakagawa et al., 
2017).  There were a total of four psychiatrists, one clinical psychologist with a master’s degree, 
and one psychiatric nurse who provided cognitive-behavioral therapy to participants.  The 
therapists were trained in cognitive-behavioral therapy for an average of 2.1 years and had 
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treated an average of 12.5 patients prior to the study.  Training in cognitive-behavioral therapy 
included a two-day intensive workshop and two-hour onsite group supervision sessions every 
two weeks from a cognitive-behavioral therapy supervisor.  Also, therapists were assessed for 
following procedures and guidelines using the Cognitive Therapy Rating Scale, in which all 
therapists passed with a score of > 40 (Nakagawa et al., 2017).  Patients who maintained 
treatment, as usual, underwent medication management and received education on medication 
dosage, schedules, reviews of the positive adverse side-effects, and were given supportive 
guidance from their therapists.  Depressive symptoms were monitored using the Quick Inventory 
of Depressive Symptomatology Self Report (QIDS-SR) and was conducted during each visit.  
Pharmacotherapy was not restricted in any manner, however, “treatments were in line with 
practice guidelines for depression care” (Nakagawa et al., 2017).  Furthermore, the seven 
therapists assigned to the study evaluated subjects for medication every two weeks for 10-15 
follow up sessions.  All subjects in the treatment-as-usual group were not provided any form of 
cognitive-behavioral therapy as an intervention for depression during the entire study period.  
Subjects in the treatment-as-usual group with cognitive-behavioral therapy were treated for 16 
weeks.  Following the 16-week period, subjects were “assessed at 6 time points; baseline (at 
randomization); 8 and 16 weeks post-randomization; and 3, 6, and 12 months after the end of the 
16-week intervention” (Nakagawa et al., 2017). 
 Nakagawa et al.’s (2017) analysis of the data presented at the completion of their study 
showed beneficial outcomes for the alleviation of depressive symptoms when adding cognitive-
behavioral therapy to antidepressant medication for the treatment of major depressive disorder.  
Moreover, the alleviation of depressive symptoms at the completion of 16-weeks of treatment 
was greater in the cognitive-behavioral therapy group than in the treatment as usual group and 
   52 
 
the least squares mean changes in GRID-HDRS17 was −12.7 vs −7.4, respectively.  The 
between-group mean difference was significant as well at −5.4; 95% CI, −8.1 to −2.6; P < .001. 
According to Nakagawa et al. (2017), “the beneficial effects of CBT were maintained over the 
12-month follow-up and were confirmed at 3 months (−13.2 vs −9.5; difference = −3.7; 95% CI, 
−6.4 to −0.9; P = .01), at 6 months (−14.9 vs −11.5; difference = −3.4; 95% CI, −6.2 to −0.6; P = 
.02), and at 12 months (−15.4 vs −11.0; difference = −4.4; 95% CI, −7.2 to −1.6; P = .002).”  
Interestingly, subjects allocated to the cognitive-behavioral group were 2.4 times more likely to 
have a response to treatment at 16-weeks in comparison to the treatment-as-usual group, while 
the benefits of cognitive-behavioral therapy in conjunction with antidepressant medication were 
confirmed at 3, 6 and 12 months.   
 The study by Nakagawa et al. (2017) had several strengths and weaknesses.  An 
important strength of the study was the high rate of cognitive-behavioral therapy completion at 
97.5% and a low dropout rate of 8.8% which translates to a highly motivated subject population.  
Meanwhile, one limitation presented here is that the highly-motivated nature of participants 
makes it difficult to generalize these results to the average population.  Also, the small sample 
size of only 80 patients of Japanese origin does not allow for the generalization of results to other 
population demographics.  Nakagawa et al. (2017) state that the experience levels of the 
therapists had a graded effect on the degree of alleviation of depressive symptoms in 
participants, i.e., the psychiatrists with more education and experience had more beneficial 
effects on patients.  The researchers state that “the possible contribution of the variance of non-
protocol–based therapeutic effects among different therapists should be acknowledged.  Patients 
with difficult-to-treat depression were reported to show differences in CBT response that were 
associated [the] with therapists’ experience levels.”  For this reason, a standardization of training 
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and education for the treatment of depression with cognitive-behavioral therapy, with 
“supervision and technical assistance, is crucial for implementing evidence-based CBT” and 
psychotherapeutics in general, and should be achieved by professionals responsible for 
counseling patients suffering from major depression (Nakagawa et al., 2017).  Another limitation 
of Nakagawa et al.’s (2017) study is researchers were unable to fully control antidepressant 
medication and antidepressant medications were similar but not all the same.  Thus, different 
types of antidepressants may affect patients differently.  Additionally, since there was no control 
group for patients receiving cognitive-behavioral treatment alone, the effects of cognitive-
behavioral therapy cannot be established.  While strengths and limitations of Nakagawa et al.’s 
(2017) study do exist, a combination approach of psychotherapeutics and pharmacotherapy, 
specifically cognitive-behavioral therapy and antidepressants, is beneficial to patients with major 
depressive disorder.  Furthermore, for patients with comorbid depression and cardiovascular 
disease, cognitive-behavioral therapy may be beneficial for both health conditions. 
Cognitive-behavioral therapy has been established as an effective treatment for patients 
suffering from major depression (Hensley, Nadiga, & Uhlenhuth, 2004).  Researchers Hensley et 
al. (2004) aimed to further investigate the effects of cognitive-behavioral therapy for the long-
term treatment and prevention of major depressive disorder, and its effectiveness as compared to 
traditional medical treatment using tricyclic antidepressants.   According to Hensley et al. (2004), 
“few clinicians expect acute treatment of depression with antidepressant medication to prevent 
long-term relapse of the illness, some practitioners of cognitive therapy report long-term 
effectiveness in preventing relapse after short-term treatment.”  Thus, Hensley et al. (2004) 
reanalyzed follow-up using intent-to-treat principles to assess the long-term effects of the acute 
treatment of depression treated with cognitive therapy.  A total of five trials published between 
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1981 and 1992 that compare cognitive-behavioral therapy to tricyclic antidepressants met the 
inclusion and exclusion criteria.  Results of the meta-analysis indicated that cognitive-behavioral 
therapy offers a more beneficial long-term treatment of major depression as compared to 
tricyclic antidepressants (Hensley et al., 2004).  Given the relevance of psychological well-being 
to promoting cardiovascular health, cognitive behavior therapy for depression likely plays a dual 
role in reducing the risk for CVD.   
Other Non-Pharmaceutical Therapies for Mental and Cardiovascular Health 
There is a lack of research on the effects of psychotherapy on comorbid depression and 
cardiovascular disease.  However, several studies do investigate the influence of other forms of 
non-pharmacotherapy for cardiovascular health and subsequently mental health.  Such therapies 
include meditation, exercise therapy, acupuncture, and musical therapy.  The current research 
looking into the possible links between meditation and heart disease focus on the physiological 
response to stress, smoking cessation, blood pressure reduction, insulin resistance and metabolic 
syndrome, endothelial function, inducible myocardial ischemia, and the primary and secondary 
prevention of cardiovascular disease.   
A study by Levine et al. (2017) aimed to discover the impact of meditation on 
cardiovascular risk reduction.  According to Levine et al. (2017), the quality of data on current 
research is only satisfactory and the availability of studies is low.  Education, a modification in 
lifestyle behaviors, and pharmaceutical interventions have decreased the prevalence of 
cardiovascular risk factors in the United States and in the developed world.  As indicated in 
Turner et al.’s (2012) study, cardiac patients receiving group cognitive behavior therapy who 
reported excess alcohol consumption and smoked cigarettes and “who did not meet remission 
criteria at 12 months had significantly higher baseline Beck Depression Inventory-II scores, 
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more visits to health professionals in the 12 months prior to baseline and were more likely to 
smoke and/or drink alcohol over recommended levels at baseline.  Furthermore, despite the 
improvements described by Levine et al. (2017), cardiovascular disease remains the leading 
cause of death around the world.  The practice of meditation dates back to 5000 B.C. and is a 
common practice in both Buddhist and Hindu cultures, and can be found in historic texts of 
Christianity, Judaism, and Islam.  Levine et al. (2017) state that “in the traditional context, 
meditation refers to a family of mental practices that are designed to improve concentration, 
increase awareness of the present moment, and familiarize a person with the nature of their own 
mind.  In a more general and contemporary context, meditation can be categorized as primarily 
focused attention, mindfulness, loving kindness and compassion, or mantra repetition, although 
there is usually an overlap between the focuses.”  According to the National Health Interview 
Survey, approximately 8% of Americans engage in some form of meditation practice, and 
between 14% and 24% of patients with cardiovascular disease report taking part in some form of 
mind-body therapy, while about 2% to 3% of cardiac patients engage in some sort of meditation 
therapy (Levine et al., 2017).  One of the major advantages of meditation is its low cost.  
Compared to a $200 billion-dollar U.S. healthcare expense on patients with CVD each year 
(which is expected to double or triple in the next few decades), meditation can be easily 
incorporated into one’s daily life through learned publications, internet sources, audio media, as 
well as inexpensive courses (Levine et al., 2017).  For this reason, meditation can be a cost-
effective treatment option for depression and lowering the risk of cardiovascular disease, and 
may be combined with conventional medical practice using pharmacology when appropriate for 
the patient.  The following study by Levine et al. (2017) was commissioned by the American 
   56 
 
Heart Association to systematically review the association between meditation and 
cardiovascular disease.   
To further the discussion on meditation and health, it is imperative to understand the 
neurophysiological and neuroanatomical influences of meditation.   According to Levine et al. 
(2017), over two decades of scientific research from over twenty universities has suggested the 
profound ability for meditation to alter the human brain.  While “most forms of meditation 
engage regions in the brain that regulate attention and emotion…the adult brain can undergo 
changes through a process called neuroplasticity, which may include development of new 
circuits (“rewiring”) and/or neurons” (Levine et al., 2017).  Various forms of sitting meditation 
also have an effect on neural circuits that include “different sectors of the prefrontal cortex and 
anterior cingulate cortex, the insula, and the midline regions that are important in default mode 
function” (Levine et al., 2017).  Furthermore, studies that examined loving-kindness and/or 
compassion meditation show alterations in the subcortical circuits of the brain which have a 
direct influence on human emotional processing, including the amygdala and the ventral 
striatum.  In addition, research on the impact of meditation on the brain has also shown the 
beneficial effects of meditation on the human physiological basal state, physiological responses, 
and cardiovascular risk (Levine et al., 2017).  However, the reader must be informed that these 
studies were limited in the number of participants involved which could reduce the significance 
of the data presented.  Also, different types of meditation will pose different types of 
neurological, physiological, and psychological responses in the patient and should be further 
investigated.   
In their research, Levine et al. (2017) used PubMed, Google, and Google Scholar to 
search for articles linking the effects of meditation on cardiovascular disease.  Search terms 
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included meditation, stress, blood pressure, hypertension, smoking, tobacco use, insulin 
resistance, metabolic syndrome, atherosclerosis, endothelial function, myocardial ischemia, 
primary prevention, and secondary prevention.  The review was limited to practices of sitting 
meditation and did not include any type of practice that consisted of both mental and physical 
practices, i.e. tai-chi, qigong, and yoga, as research shows physical activity reduces the risk of 
cardiovascular disease and this would be confounding to the data.  Levine et al. (2017) isolated 
studies that involved quality information on meditation and cardiovascular risk reduction; 
meditation and the psychological, psychosocial, and physiological responses to stress; the effects 
of meditation on blood pressure, insulin resistance, and metabolic syndrome; and the effects of 
meditation on subclinical atherosclerosis and endothelial function.  
Numerous studies were found by Levine et al. (2017) that investigated the link between 
meditation, cardiovascular risk reduction, and the psychological, psychosocial, and physiological 
human response to stress during meditation practice.  Most of the studies suggested the 
amelioration of the perceived levels of stress, mood, anxiety, depression, quality of sleep, and 
improved overall wellbeing by subjects following meditation therapy.  These studies were 
exclusive of randomized controlled trials.  However, only a few of the studies included 
participants with cardiovascular disease.  One of the studies examining 60 patients from a private 
cardiology clinic found that “those randomized to 8 weeks of mindfulness-based stress reduction 
(primarily using meditation techniques) had significantly lower perceived stress and anger than a 
comparison control group” and researchers found that meditation strongly improved overall 
quality-of-life (Levine et al., 2017).  Hence, the psychological component of these studies is 
important to consider when discussing the interrelationship between psychotherapy (meditation), 
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depression, and cardiovascular disease.  Additionally, this association further advocates the 
beneficial relationship between positive thoughts and physical wellbeing.   
Meditation not only improves psychological, psychosocial, and physiological health, but 
a few high-quality, randomized studies have found it also lowers blood pressure.  According to 
Levine et al. (2017), “a pilot study of 83 predominantly hypertensive blacks randomized to a 
mindful meditation program or control social support group, [where] a 11/4 mm Hg decrease in 
systolic/diastolic blood pressure was observed in those randomized to 8 weeks of treatment and 
an analysis adjusted 22/17 mm Hg difference in blood pressure between the 2 groups at follow-
up.”   Strengths of the study include its 100% data ascertainment, over 80% compliance rate 
from patients at visit to the clinic, and “measured blood pressure with an unattended manual 
device (a rigorous protocol with measurements 7–15 mm Hg lower than typical office readings)” 
(Levine et al., 2017).   Furthermore, another randomized study of 201 African American men 
and women “with angiographically documented coronary artery disease randomized to 
transcendental meditation or health education, after 5.4-year follow-up found a 4.9 mm Hg lower 
systolic blood pressure, [one] of numerous secondary study end points, in those randomized to 
transcendental meditation than in those randomized to health education, primarily because of an 
increase in blood pressure in the health education group” (Levine et al., 2017).  The relationship 
between blood pressure and the increased risk of cardiovascular disease has been well-
established in the medical community.  Research suggesting the association between meditation 
(affecting the mind and body) to a reduction in blood pressure strengthens the claim that 
therapies for the mind have an influence on our physical health, particularly when discussing 
heart health.  Furthermore, a 2013 American Heart Association (AHA) scientific statement on 
non-pharmaceutical approaches to lowering blood pressure concluded that “transcendental 
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meditation modestly lowers blood pressure and that its use may be considered” (Levine et al., 
2017).  In this announcement, the AHA also made note of the insufficient number of high-quality 
studies investigating other forms of meditative therapies and their effects on lowering blood 
pressure (Levine et al., 2017).  One limitation of the research available between blood pressure 
and meditation is the average completion rate (percent of patients who completed all training and 
post-test) for the studies, which was only 63% (Levine et al., 2017).  Further research on the 
effects of meditation on blood pressure should be investigated to increase the strength of any 
positive association between the two variables.  Furthermore, another smaller scale study looking 
at the relationship between blood pressure and meditation found neurophysiological changes in 
patients with hypertension and chronic kidney disease.  A total of 15 participants with 
hypertension and chronic kidney disease were evaluated following engaging in mindful 
meditation.  Patients reported a decrease in muscle sympathetic nervous activity and blood 
pressure.  However, long-term effects of meditation on hypertension and chronic kidney disease 
could not be established (Levine et al., 2017).  The study was limited by its small sample size.   
Researchers have also attempted to discover whether a correlation exists between 
meditation and metabolic syndrome.  Metabolic syndrome is a risk factor for diabetes mellitus 
and cardiovascular disease—thus the potential for meditation to reduce the conditions and 
symptoms related to metabolic syndrome is valuable for also reducing the risk for cardiovascular 
disease.  One study with a total of 103 subjects who were diagnosed with coronary artery disease 
were randomized into two groups—a control group in which patients received health education, 
or a group that participated in transcendental meditation.  The group that engaged in 
transcendental meditation experienced improved insulin resistance (Levine et al., 2017).  The 
study also evaluated the effects of yoga, and a vegetarian diet on metabolic syndrome.  This 
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multimodal approach to the study limited its conclusions as yoga and a vegetarian diet are 
confounding variables that most likely have an effect on metabolic syndrome.  Thus, this study 
was limited by its multimodal experimental setting and moderate sample size.  
The association between metabolic syndrome, cardiovascular disease, and non-pharmacotherapy 
is novel and a small number of studies exist that delve into this topic.  Thus, the medical and 
scientific community should encourage further research on the effects of non-pharmacotherapy 
on metabolic syndrome—a strong risk factor for cardiovascular disease. 
In their article, researchers Levine et al. (2017) also discuss the association between 
meditation and subclinical atherosclerosis.  Atherosclerosis is a condition in which the arteries 
have become hardened by the buildup of plaque overtime, leading to an increased risk for 
cardiovascular disease since blood circulation is compromised (Levine et al., 2017).  Levine et 
al. (2017) found only one study investigating the effects of meditation on the progression of 
atherosclerosis.  A total of 138 hypertensive African Americans were randomized to either a 
group partaking in transcendental meditation or a control group in which participants were 
placed in a health education program.  Subjects in both the transcendental meditation group and 
the control group were followed for an average of 7 months.  Data on carotid intimal thickness 
was collected during the 7-month follow-up (Levine et al., 2017).  One limitation of the study 
was the high attrition rate of 57% of patients who did not complete the studies total duration.  
With those subjects who completed the study, the meditation group showed carotid intimal 
thickness regression, “whereas progression occurred in the control group, with the difference 
between the 2 groups being statistically significant” (Levine et al., 2017).  Therefore, researchers 
concluded that transcendental meditation had positive effects on atherosclerosis and thus may 
reduce the risk for cardiovascular disease (Levine et al., 2017).  Another limitation of the study 
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to consider is the study population demographics.  Since only African American men were 
included, results of the study cannot be applied to women or people of other races or ethnicities.  
Moreover, Levine et al. (2017) found another study of 57 healthy adults aged 65 or older.  
Participants were randomized to one of three interventions: “a transcendental meditation 
program that also included diet, exercise, and vitamin treatment; a diet/exercise/vitamin arm 
without the meditation component; or a usual care arm” (Levine et al., 2017).  After one year of 
follow-up, the group who engaged in meditation presented with a reduction in carotid intimal 
thickness which was not observed in the other two intervention groups.  The multimodal study 
design is a limiting factor of the study since the meditation group also included a healthy diet 
plan, exercise, and vitamin treatment.  A reduction in intimal carotid artery thickness could be a 
result of diet, exercise, and the vitamin regimen independently, or a result of the combination of 
treatment modalities. 
Inducible myocardial ischemia is another important cardiovascular condition to consider 
for treatment with non-pharmacologic techniques.  Inducible myocardial ischemia occurs when 
blood flow to the heart is reduced, which prevents the heart muscle from receiving appropriate 
levels of oxygen (Mayo Clinic, 2019).  Reduced blood flow to the heart is usually a result of a 
partial or complete blockage of the heart’s arteries.  Serious complications of inducible 
myocardial ischemia include an increased risk for heart attack, irregular heart rhythm, or heart 
failure (Mayo Clinic, 2019).  While inducible myocardial ischemia significantly increases the 
risk for cardiovascular complications and even death, a lack of studies are available that 
investigate the influence of non-pharmacotherapeutics on myocardial ischemia.  However, a 
study dating back to 1996 gathered 21 subjects with coronary artery disease.  According to 
Levine et al. (2017), “7.6 months of transcendental meditation led to significant increases in 
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exercise duration (15%) and maximum work load (12%) compared with wait-listed controls, as 
well as lower rate-pressure products at given workloads and significantly delayed onset of ST 
depression.”  ST depression is a type of finding on an electrocardiogram in which the trace in the 
ST segment is abnormally low below the baseline and “ST depression is associated with acute 
coronary syndromes (ACS)—both acute ischemia and acute infarction; this electrocardiographic 
pattern, however, may also be found in patients with non-ischaemic events, such as left bundle 
branch block (LBBB), left ventricular hypertrophy (LVH), and those with therapeutic digitalis 
levels” (Pollehn, Brady, Perron, & Morris, 2002).  Furthermore, another study conducted in 1983 
assessed 43 patients with ischaemic heart disease that took a combination treatment approach for 
CVD.  Treatment for these subjects combined stress management (meditation and 
stretching/relaxation exercises) and a vegan-based diet.  Patients were analyzed after 24 days of 
multimodal therapy.  Results of the study indicated a 44% increase in exercise duration, 55% 
increase in total work, and improved exercise ejection fraction and regional wall motion, 
“whereas no significant changes occurred in the control group” (Levine et al., 2017).  
Limitations of the study included the small sample size and the confounding variables presented 
by the multimodal approach to treatment.  Thus, meditation alone cannot be independently 
deemed responsible for the improved changes in patients receiving treatment, as stretching, 
relaxation techniques, and a vegan diet may all lead to improvements in cardiovascular patient 
outcomes.   
Levine et al.’s (2017) meta-analytic review also looked into research on the effects of 
meditation on the primary prevention of cardiovascular disease.  According to the authors, recent 
Cochrane reviews have “concluded that no properly conducted randomized, controlled trials 
have assessed its role in the primary prevention of cardiovascular mortality or nonfatal primary 
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end points. This is largely because the relevant studies are small, with short-term follow-up and 
carried out in predominantly healthy participants” (Levine et al., 2017).  However, a systematic 
review of randomized controlled trials investigating the link between meditation and the primary 
prevention of cardiovascular disease found that various non-pharmacotherapies including 
meditation, yoga, and a healthy diet were associated with improvements in physical and mental 
quality-of-life, depression and anxiety, and systolic and diastolic blood pressure—all of which 
have been shown to reduce the risk of cardiovascular disease in patients.  Thus, while there is a 
paucity of research available delving into the relationship between meditation and CVD, it can 
be stated with confidence that cardiovascular health and psychological health are interrelated and 
a multimodal approach using both conventional and non-pharmaceutical therapies for their 
treatment is beneficial for overall quality-of-life. 
The scientific and medical communities agree that the benefits of physical exercise are 
numerous for physiological and psychological health, as well as for the overall quality-of life.  A 
study by Knapen, Vancampfort, Moriën, and Marchal (2014) investigated the influence of 
exercise therapy on mental and physical health on patients with major depression.  According to 
Knapen et al. (2014), “depression is associated with a high incidence of co-morbid somatic 
illnesses, especially cardiovascular diseases, type 2 diabetes and metabolic syndrome.” 
Additionally, “depressed persons have approximately a two-fold increased risk of having or 
developing cardiovascular disease.  Further, after a cardiovascular event, the risk of onset of 
depression is increased, resulting in poorer cardiovascular outcomes.  Metabolic syndrome, a 
constellation of cardiovascular risk factors including (abdominal) obesity, hypertension, 
dyslipidemia and hyperglycemia, has been suggested to be one possible pathway linking 
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depression and cardiovascular disease” (Knapen et al., 2014).  Again, the link between 
depression and cardiovascular disease is strongly suggested.   
Moreover, research has shown a strong connection between neuropsychiatric disorders, 
particularly major depression, and type II diabetes.  According to Lyra e Silva, Lam, Soares, 
Munoz, Milev, and De Felice (2019), evidence shows that type II diabetes increases the risk of 
developing dementia, neuropsychiatric and mood disorders and “evidences of the involvement of 
insulin signaling on brain mechanisms related to depression indicates that insulin resistance, a 
hallmark of type 2 diabetes, could develop in the brains of depressive patients.”  Some studies 
show a bidirectional relationship between depression and type II diabetes and a recent report 
indicated that the severity of depression in children predicted the future development of insulin 
resistance.  Furthermore, the more severe the insulin resistance detected in depressed obese 
youth, the more significant the symptoms of depression as well as the dysfunction of the anterior 
cingulate cortex-hippocampal motivational network (Lyra e Silva et al., 2019).  Recent post-
mortem analysis of the brain of patients who were suffering from diagnosed mental illness 
showed a correlation between “gene expression of proteins involved with both the dopaminergic 
system and insulin signaling, supporting the idea that insulin could regulate the dopaminergic 
response” (Lyra e Silva., 2019).  To further elucidate the connection between insulin resistance 
and depression, Papazoglou et al. (2011) suggest that several hormones and neurotransmitters in 
the brain regulate the action of insulin in the body.  The neurotransmitter serotonin (5-HT) is of 
particular importance for the control of food intake and energy homeostasis, as well as for the 
alleviation of mood, sleep, satiety (Papazoglou et al., 2011; Shabbir et al., 2013).  Furthermore, 
according to Shabbir et al. (2013),  
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“the serotonin precursor, tryptophan, can readily pass through the blood-brain barrier. 
Tryptophan is converted to 5-HT by tryptophan hydroxylase and 5-HTP decarboxylase, 
respectively, in the presence of pyridoxal phosphate, derived from vitamin B6. Hence 
diets poor in tryptophan may induce depression as this essential amino acid is not 
naturally abundant even in protein-rich foods. Tryptophan-rich diet is important in 
patients susceptible to depression such as certain females during pre and postmenstrual 
phase, post-traumatic stress disorder, chronic pain, cancer, epilepsy, Parkinson's disease, 
Alzheimer's disease, schizophrenia, and drug addiction.” 
From this research, the relationship between insulin resistance, depression and mood, sleep, and 
cardiovascular disease is further highlighted, and additional research between these connections 
should be investigated in the future.   
Researchers Knapen et al. (2014) conducted a meta-analytic review of randomized 
control trials from the Cochrane Collaboration that investigated the effects of exercise therapy 
or no treatment on patients with major depression.  A total of four studies met inclusion and 
exclusion criteria set forth by Knapen et al. (2014).  The researchers wanted to answer specific 
questions regarding exercise therapy for depression including whether exercise is more effective 
than no treatment for depression; whether exercise is more effective than antidepressant 
medication for depression; is exercise more effective than psychological therapies or other 
nonmedical treatments for depression; and how patients accept exercise for the treatment of 
depression (Knapen et al., (2014).  Inclusion criteria involved subjects diagnosed with major 
depression who were at least 18-years-old and patients had to be engaging in physical exercise 
that met the criteria for the definition of “exercise.”  After a review of the meta-analytic reviews 
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available that fit the inclusion and exclusion criteria set forth by Knapen et al. (2014), 
researchers pinpointed four articles matching their interests.   
General results of Knapen et al.’s (2014) meta-analysis concluded that exercise is an 
effective non-pharmaceutical treatment for depression.  Moreover, in patients with mild to 
moderate depression, exercise was as effective for the reduction of depressive symptoms as 
antidepressant medication (Knapen et al., (2014).  Not only was exercise found to be an effective 
treatment for patients with major depression, but also “exercise therapy also improves physical 
health (e.g. metabolic syndrome), body image, and patient’s coping strategies with stress, 
quality-of-life, and independence in activities of daily living in older adults” (Knapen et al., 
2014).  A more recent meta-analysis including 18 reviews with 5531 subjects found that 
metabolic syndrome occurs frequently in depressed patients with an average of 30.5% percent of 
those suffering from major depression also suffering from metabolic syndrome.  It is important 
to reiterate the key understanding that the cluster of conditions that metabolic syndrome 
comprises of, all increase the risk for cardiovascular disease.  Furthermore, Knapen et al. (2014) 
found that the relative risk for metabolic syndrome in patients with depression was 1.5 times 
higher than the general population—with no difference found between incidence rate in men and 
women, or age in the lifespan.  Thus, physical exercise is indicated in the treatment of both 
depression and cardiovascular disease, as well as in reducing the risk factors associated with both 
conditions. 
Knapen et al. (2014) located another meta-analytic review on the bi-directional 
relationship between metabolic syndrome and major depression.  The meta-analysis concluded 
that metabolic syndrome is an independent risk factor major depression and patients with 
metabolic syndrome have a higher relative risk to develop clinically diagnosed depression (OR ¼ 
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2.18) than those who do not suffer from metabolic syndrome (Knapen et al. (2014).   According 
to Knapen et al. (2014), “the positive bi-directional longitudinal association between depression 
and metabolic syndrome means that depression is causing metabolic syndrome and vice versa. 
This association suggests a possible pathophysiologic overlap.  More specifically, elevated 
cortisol, epinephrine, and norepinephrine secretion due to hyperactivity of the hypothalamic–
pituitary adrenal (HPA) axis, (pro)-inflammatory processes, oxidative stress, autonomic nervous 
system dysregulation, and insulin resistance are all interacting biological mechanisms that may 
mediate the association between depression and metabolic syndrome.”  The researchers also 
conclude that depression and metabolic syndrome are associated with an increased risk of 
mortality and morbidity, most likely the result of an increased risk for cardiovascular disease and 
diabetes mellitus type II.  Thus, exercise therapy also plays a dual role in the improvement of 
both depression and cardiovascular disease in patients suffering from either one or both health 
conditions.  
Acupuncture is another form of non-pharmacotherapy that has become more popular for 
the treatment of a variety of health conditions, including depression and cardiovascular related 
disorders.  A case study by Lin, Qin, and Wang (2018) discusses the effects of Traditional 
Chinese medicine (TCM) acupuncture combined with musical therapy for the treatment of post-
stroke depression (PSD).  In the United States, post-stroke depression is typically treated using 
western medical practices mostly consisting of a prescription medication regimen that reportedly 
increases the pain and suffering of patients due to adverse side-effects (Lin et al., 2018).  For this 
reason, researchers Lin et al., (2018) aimed to discover the influence of more natural routes to 
the treatment of post-stroke depression using acupuncture and musical therapy.  The patient in 
their case report was a 53-year-old male who suddenly developed weakness in the right limbs 
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one month prior to review.  The patient’s stroke diagnosis was later complicated by post-stroke 
depression and a generally pessimistic outlook on life (Lin et al., 2018).  According to Lin et al., 
(2018) “Transcranial Doppler (TCD) showed occlusion of extracranial segment of internal 
carotid artery (ICA) on [the] left side, opening of exterior branches of ICA on [the] left side, 
opening of [the] exterior left ramus communicans, severe stenosis of terminal ICA on [the] right 
side, and severe stenosis of initial middle cerebral artery (MCA) on [the] right side.”  Lin et al. 
(2018) treated the patient with acupuncture with specific acupoints selected including:  
“Baihui (GV 20), 3 brain acupoints consisting of Shenting (GV 24) and Benshen (G 13) 
of both sides, 3 hand acupoints comprising of Quchi (LI 11), 35 Waiguan (SJ 5) and 
Hegu (LI 4) on right side, Shousanli (LI 10) on right side, and 3 foot acupoints consisting 
of Zusanli (ST 36), Sanyinjiao (SP 6) and Taichong (LR 3) on right side. The location of 
acupoints referred to international standards. Baihui was located in the brain, 5 cun from 
the midpoint of anterior hairline straightly, or the midpoint of the line of 2 ear tips” (Lin 
et al., 2018).   
The musical therapy administered to the patient along with acupuncture is referred to as 
Traditional Chinese medicine five-element musical therapy.  This form of therapy asks the 
patient what type of music he/she enjoys listening to, and is usually selected based on the 
patient’s emotions, and based on the principles of mutual generation, mutual suppression, and 
mutual correspondence (Lin et al., 2018).  After being treated for post-stroke depression 
simultaneously with acupuncture and musical therapy, Lin et al. (2018) found that with treatment 
of the mind and body, “the patient’s neurological deficit score, HAMD scale and ADL scale 
scores were improved significantly, and the levels of TNF-α, IL-6, hs-CRP and homocysteine, 
biological indicators that were in close association with the pathogenesis of PSD, were reduced 
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prominently, with satisfactory therapeutic efficacy obtained.”  Thus, while acupuncture and five-
element musical therapy suggest a strong benefit for this case study of a post-stroke depressed 
patient, one major limitation of the study is the small sample size, limited demographics, and 
single sex study parameters.  Therefore, in order to further establish the benefits of acupuncture 
and musical therapy for the treatment of cardiovascular and neurological related illnesses, 
accompanied with depression, further study must be conducted using larger and more diverse 
populations.  Additionally, the case study by Lin et al. (2018) administered the simultaneous 
treatment of acupuncture and musical therapy.  Thus, it becomes difficult to isolate the true 
influence of each non-pharmacologic therapeutic modality independently.     
The predominance of research investigating the link between depression and 
cardiovascular health delves into how psychological and emotional well-being influence health 
outcomes in patients with cardiovascular disease, as well as in patients with the absence of heart 
disease.  Researchers DuBois, Lopez, Beale, Healy, Boehm, and Huffman (2015) investigated 
the correlation between positive psychological constructs (optimistic viewpoints and mentality) 
on various health-related outcomes in patients with cardiovascular disease.  DuBois et al. (2015) 
completed a systematic review of prospective observational studies using the search engines 
PubMed and PsycINFO from January 2014 to the time of their proposed research (2015).  
Inclusion criteria consisted of any article discussing the “effects of a positive psychological 
construct on subsequent health-related outcomes (including mortality, hospitalizations, self-
reported health status) in patients with established heart disease” (DuBois et al., 2015).  A total 
of 30 studies met inclusion criteria.  Researchers found that among patients with cardiovascular 
disease, optimism and a positive psychological state was prospectively associated with cardiac 
health but additional research must be conducted to confirm these findings.   
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Patients who have recently experienced cardiac health events are most often treated for 
depression or anxiety using psychological measures with the intention of improving the general 
health outcomes.  Richards et al. (2017) were interested in discovering the effects “of 
psychological interventions (alone or with cardiac rehabilitation) compared with usual care 
(including cardiac rehabilitation where available) for people with CHD on total mortality and 
cardiac mortality; cardiac morbidity; and participant-reported psychological outcomes of levels 
of depression, anxiety, and stress; and to explore potential study-level predictors of the 
effectiveness of psychological interventions in this population.”  The trial participants were 
mostly men between the ages of 53 and 67 years.  After performing a meta-analysis of 35 studies 
included 10,703 people with cardiovascular disease, the authors concluded that psychological 
treatments for people with cardiovascular disease had no impact on total mortality, the risk of 
revascularization procedures, or on the incidence of myocardial infarction that was non-fatal.  
However, “cardiac mortality was reduced and psychological symptoms (depression, anxiety, or 
stress) were alleviated; the GRADE assessments suggest considerable uncertainty surrounding 
these effects” (Richards et al., 2017).  Moreover, according to Wells et al. (2018), there is a lack 
of psychological intervention for anxiety or depression for patients attending cardiac 
rehabilitation services.  Despite the lack of mental health integration in cardiac rehabilitation 
settings, anxiety and depression among cardiac patients remains high.  Even with the 
advancements in treatments and therapy for atherosclerosis, cardiovascular disease remains the 
leading cause of death in the U.S. and worldwide (Levine et al., 2017; NIMH, 2017; WHO, 
2018).    
A strong, bidirectional and graded relationship exists between depression and 
cardiovascular disease.  In the enhancing recovery in coronary heart disease (ENRICHD) trial, 
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74% of patients who had recently suffered from a myocardial infarction were also diagnosed 
with major depression (Dhar & Barton, 2016).  While an average of 10% of the general 
population are diagnosed with major depression, this percentage increases to 40% in people who 
have suffered a major cardiac event, 30% in people who have cardiovascular disease, and in 50% 
of those recovering from coronary artery bypass surgery (Dhar & Barton, 2016).   Therefore, the 
alleviation of depression should facilitate the successful alleviation of cardiovascular disease, 
and vice-versa.   
The majority of research investigating the effects of various forms of non-
pharmacotherapy for the treatment of depression and cardiovascular disease has shown benefits 
for patients.  Psychotherapy is a form of non-pharmacotherapy which encompasses any 
intervention where the core element is verbal communication between the depressed subject and 
the therapist.  Psychotherapy has been shown to improve depressive symptoms and quality-of-
life domains including social relationships, physical abilities, mental health functioning, and 
engagement in daily activities—all of which patients with depression experience deficits.  
Psychotherapy also improves the mental and physical health of patients.  Short-term 
psychotherapy of 8-or-fewer sessions is shown to be as effective in reducing symptoms of 
depression as standard duration psychotherapy consisting of 12 to 20 sessions.  Effect sizes for 
brief psychotherapy are modest but at present appear comparable to those observed in trials of 
antidepressant medications and of standard duration psychotherapies.  Moreover, for patients 
with severe depression, 16 sessions of psychotherapy were found to be more effective in 
reducing symptom severity than only 8 sessions.   
A common form of psychotherapy, cognitive behavior therapy, improves symptoms of 
depression in cardiac patients.  Research shows no significant difference in patient outcomes 
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between cognitive behavior therapy and brief psychotherapy on depression scales: BDI-II, major 
rates of depression, or the HADS-A score.  While no significant difference exists between 
cognitive behavior therapy and brief psychotherapy for depressed cardiac patients, group 
psychotherapy sessions reduce symptom severity in these patients.  Additionally, short-term 
cognitive behavior therapy is an effective treatment option for acute unipolar depression, and 
short-term psychodynamic psychotherapy (PAT) was found equally effective compared to short 
term CBT and other psychotherapies (Leuzinger-Bohleber et al., 2019). 
For patients with pharmacotherapy treatment-resistant depression, cognitive-behavioral 
therapy is equally effective for depression as antidepressant therapy alone, and combining 
cognitive-behavioral therapy and antidepressant therapy is even more effective (Nakagawa et al., 
2017).  Furthermore, psychotherapy has greater positive effects on mental health as compared to 
physical health.  However, despite the smaller effect, physical health is an important predictor of 
cardiovascular health (Chaddha et al, 2016).  Additionally, depressed persons have 
approximately a two-fold increased risk of having or developing cardiovascular disease.  
Following a cardiovascular event, the risk of onset of depression is increased, resulting in poorer 
cardiovascular outcomes.  Given the prevalence of comorbid depression and cardiovascular 
disease, cognitive behavior therapy for depression likely plays a dual role in reducing the risk for 
cardiovascular disease. 
Moreover, a beneficial relationship exists between positive thoughts and physical 
wellbeing and the practice of meditation is shown to reduce both depression and cardiovascular 
symptoms in patients (Levine et al., 2017).  Eight weeks of mindfulness-based stress reduction 
meditation reduces perceived stress and anger in cardiac patients, and meditation has been shown 
to improve overall quality-of-life.  Meditation therapy, particularly mindful meditation, has also 
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been shown to lower blood pressure and the relationship between blood pressure and the 
increased risk of cardiovascular disease is well-established in the medical community.  
Furthermore, transcendental meditation is shown to lower blood pressure in African American 
men and women with angiographically documented coronary artery disease, and decreases 
carotid artery thickness in cardiac patients (Levine et al., 2017).  Researchers Levine et al. (2017) 
concluded that transcendental meditation has positive effects on atherosclerosis and thus may 
reduce the risk for cardiovascular disease.  Therefore, therapies of the mind undoubtedly have an 
influence on our physical health, especially when discussing heart health.   
Acupuncture is another non-pharmacotherapeutic technique shown to be effective in 
reducing the symptoms of depression in post-stroke cases.  After being treated for post-stroke 
depression simultaneously with acupuncture and musical therapy, Lin et al. (2018) found that 
with treatment of the mind and body, neurological deficit scores, HAMD scale and ADL scale 
scores were improved significantly, and levels of markers for cardiovascular disease including 
TNF-α, IL-6, hs-CRP and homocysteine, were reduced significantly.  Further research is needed 
investigating the positive effects of acupuncture on comorbid depression and cardiovascular 
disease. 
Lastly, physical exercise is widely known to alleviate the symptoms of depression and 
reduce the risk of cardiovascular disease in patients and is strongly encouraged by the health care 
community (Knapen et al., 2014).  In patients with mild to moderate depression, exercise is as 
effective for the reduction of depressive symptoms as antidepressant medication (Knapen et al., 
2014).  Not only is exercise an effective non-pharmacologic treatment option for patients with 
major depression, physical exercise also improves physical health (e.g. metabolic syndrome), 
body image, and patients’ coping strategies with stress, quality-of-life, and independence in 
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activities of daily living in older adults.  Thus, physical exercise is encouraged for the 
management of both depression and cardiovascular disease, as well as in reducing the risk 
factors associated with both conditions. 
 




Depression and cardiovascular disease are two of the most common and detrimental 
disease states, with depression being the number one cause of disability and cardiovascular 
disease being the leading cause of death around the world.  While there is undoubtedly a plethora 
of advantages to conventional medicine using pharmacotherapy for the treatment of acute and 
chronic disease, there are serious fears and misunderstandings in the general public about 
pharmaceuticals leading patients to avoid compliance with physician guidance and medical 
interventions for their illnesses (American Medical Association, 2015).  As stated by the 
American Medical Association (2015), the most common reasons for non-adherence to physician 
guidance and prescribed medications include: a fear of unwanted and painful side-effects, fear of 
dependence; and the high cost of medications.  In the United States, depression and 
cardiovascular disease are typically treated using Western medical practices mostly consisting of 
a prescription medication regimen that reportedly drastically increases the pain and suffering of 
patients due to adverse side-effects (Lin et al., 2018).  Thus, it becomes imperative for the 
scientific and medical community to discover integrated and/or non-pharmaceutical routes to 
treating depression and cardiovascular disease, where patients are more likely to engage in 
positive lifestyle changes—thereby reducing or potentially avoiding the fears associated with 
pharmacotherapy, unless medication is otherwise indicated.    
The majority of research investigating depression and cardiovascular disease shows a 
strong bidirectional and graded correlation between the two health conditions, which are most-
often-than-not comorbid states of illness—the more severe one condition, the more severe the 
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other.  Depression has a strong worsening effect on cardiovascular disease and people with 
cardiovascular disease have higher rates of depression than the general population.  Research 
suggests that unhealthy lifestyle factors (smoking, diets high in calories, salt, and saturated fats), 
living a sedentary lifestyle, nonadherence to physician guidance and prescribed medications, 
type A personality, increased inflammation and oxidative stress, decreased heart rate variability, 
hyperactivation of the HPA axis, endocrine system dysfunction, omega-3 impairment, excessive 
stimulation of the sympathetic nervous system, nucleotide polymorphisms, circadian 
desynchronization and sleep cycle dysfunction, genetics factors, and metabolic syndrome—all 
contribute to and increase the risk for both depression and cardiovascular disease.   
Therefore, health professionals should urge the medical community to incorporate 
various forms of non-pharmacologic modalities, along with conventional approaches if 
necessary, for treating depression and cardiovascular disease.  Because the strong association 
between depression and cardiovascular disease has only been more recently studied and 
recognized by researchers and the medical community, not enough data is available on the health 
benefits of non-pharmacotherapy as it compares to medicines for the alleviation of comorbid 
depressive and cardiovascular symptoms.  However, the small number of research available on 
the influence of various non-pharmacology on depression and cardiovascular disease show 
promising results pointing to a myriad of health benefits for the treatment of depression in 
cardiac patients with both conventional and non-pharmacologic treatment, used together or 
independently as appropriate for the individual patient.  Research even shows non-
pharmacotherapy, including psychotherapy, meditation, and acupuncture to be as effective as 
antidepressant medication in treating depression (Nieuwsma et al., 2018).  
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Various forms of psychotherapy including interpersonal therapy, problem-solving 
therapy, mindfulness-based cognitive therapy, cognitive-behavioral analysis system of 
psychotherapy, dialectical behavioral therapy, functional analytic psychotherapy, acceptance and 
commitment therapy, and short-term psychodynamic therapy have all been shown to reduce the 
symptoms of depression in depressed patients, and heart disease independently of one-another, 
with or without antidepressant medication (Nieuwsma et al., 2018).  Furthermore, non-
pharmacotherapy including exercise therapy, meditation, acupuncture, and five-element musical 
therapy, were all shown to reduce the symptoms of depression and cardiovascular disease in 
patients and are indicated for the future of integrative medical practice (Levine et al., 2017; Lin 
et al., 2018).   
Finally, steering away from prescription medications when possible to alleviate or treat 
symptoms of depression and cardiovascular disease by implementing non-pharmaceutical 
treatment options for patients may be the answer to reducing disease burden in the future by 
making patients more motivated, inclined, and less fearful of addressing their health problems.  
However, when medication is necessary and indicated for the patient, an integrated approach to 
disease management using both conventional and non-pharmacologic therapies may be optimal.   
Furthermore, while various forms of non-pharmacotherapy are effective in reducing the 
symptoms of both depression and cardiovascular disease independently, it remains undetermined 
whether these treatments are effective is reducing comorbid depression and cardiovascular 
disease. 
Analysis of Strengths and Weaknesses 
Strengths.  This research paper is balanced to show the interrelationship between 
depression and cardiovascular disease, as well as the benefits of non-pharmacotherapy for the 
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treatment of both health conditions.  Most of the literature analyzed were meta-analytic reviews 
of randomized controlled trials investigating these relationships, as well as single studies where a 
randomized controlled trial was carried out to highlight any correlation between depression, 
cardiovascular disease, and non-pharmacotherapies for treatment.  
Weaknesses.  The relationship between depression and cardiovascular disease and non-
pharmacotherapy for the treatment of depression and cardiovascular disease are well 
analyzed.  However, the paucity of research available investigating the effects of diverse forms 
of non-pharmacotherapy on comorbid depression and cardiovascular disease hinders the 
scientific and medical communities’ confidence in determining non-pharmacological modalities 
and conventional medicine as a single or multimodal treatment protocol for both disease 
conditions.   While a graded and bidirectional relationship between depression and 
cardiovascular disease exists, a lack of attention is paid to the amelioration of these diseases 
using non-pharmacotherapeutics for comorbid depression and cardiovascular disease. 
Proposed Future Study 
 A graded and bidirectional relationship between depression and cardiovascular disease 
has been established and “there is no argument that depression is a risk marker for an increased 
incidence of new cardiovascular disease and a worse outcome in existing cardiovascular disease” 
(Hare et al., 2013).  However, there is a scarcity of research investigating the effects of non-
pharmacotherapy on comorbid depression and cardiovascular disease.  Therefore, future research 
exploring the effects of various forms of non-pharmacotherapy on comorbid depression and 
cardiovascular disease should be conducted to determine which are most beneficial to patients, 
and whether certain non-pharmacotherapies should be a standard treatment protocol for cardiac 
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patients with or without formally diagnosed major depressive disorder or clinical depression.  
When indicated, implementing an integrated, multi-disciplinary approach with both conventional 
and non-pharmacologic techniques for clinical depression and CVD patient care and 
management may be a key strategy for managing depression in the context of cardiovascular 
disease, or vice-versa. 
Proposed Study Design: A case series trial should be initiated using specified inclusion 
and exclusion criteria with a maximum of 20 subjects due to feasibility.   
Participants: A total of 20 patients 18-years-or-older will be gathered from the Middlesex 
Hospital Family Medicine Center, located in Middletown, Connecticut.  Participants will be 
required to sign informed consent that they are voluntarily foregoing pharmaceutical 
interventions for the management of either depression and/or cardiovascular disease and 
understand the potential health consequences.  Patients will be required to have a formal 
diagnosis and/or history of both cardiovascular disease and major depressive disorder (clinical 
depression).  Any form of cardiovascular disease including a history of myocardial infarction, 
coronary atherosclerosis, stroke, heart failure, angina, hypertension, arrythmia, atherosclerotic 
calcification, and/or heart valve problems, will be included.  A formal diagnosis of major 
depressive disorder or clinical depression will follow the criteria set form by the DSM-V.  As 
outlined in the DSM-V, to be diagnosed with major depressive disorder, patients must have at 
least five of the following symptoms of depression for at least a two-week period diagnosed by a 
licensed medical or mental health professional (at least one symptom must be a reduced interest 
or pleasure or depressed mood): depressed mood (for children and adolescents, this can also be 
an irritable mood); diminished interest or loss of pleasure in almost all activities (anhedonia); 
significant weight change or appetite disturbance (for children, this can be failure to achieve 
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expected weight gain); sleep disturbance (insomnia or hypersomnia); psychomotor agitation or 
retardation; fatigue or loss of energy; feelings of worthlessness; diminished ability to think or 
concentrate; indecisiveness; recurrent thoughts of death, recurrent suicidal ideation without a 
specific plan, or a suicide attempt or specific plan for committing suicide (Medscape, 2019). 
 The Middlesex Hospital Family Medicine Center provides patients with an Integrative 
Medicine Consultation Program offering acupuncture, yoga, nutrition planning, exercise, spinal 
manipulation, relaxation therapies, massage, mental health counseling, as well as medication and 
other conventional therapies.  Subjects will be randomly divided into four separate groups to 
either receive non-pharmacotherapy with mental health counseling using cognitive behavior 
therapy, acupuncture, meditation therapy, or all three treatments.  Subjects will be recruited 
through their primary care physicians within the Middlesex Hospital patient database.  
Advertisements will also be placed in the various medical inpatient and outpatient offices 
affiliated with Middlesex Hospital in Middletown, CT, and surrounding areas.  Patient outreach 
will also consist of an emailed newsletter, social media ads, and placing fliers in the area locally.  
All services will be provided gratis to all participants. 
 Inclusion Criteria:  The following inclusion criteria should be considered: adults 18-
years-or-older; male and female subjects; subjects formally diagnosed with any form of 
cardiovascular disease including a history of myocardial infarction, coronary atherosclerosis, 
stroke, heart failure, angina, hypertension, arrhythmia, atherosclerotic calcification, and/or heart 
valve problems.  Those diagnosed with major depressive disorder following criteria set forth by 
the DSM-V; subjects must be diagnosed or have a history of both cardiovascular disease and 
clinical depression. 
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 Exclusion criteria: Diagnosis with any form of mental illness other than major depressive 
disorder.  Any other comorbidity other than depression and/or cardiovascular disease.  Those 
already receiving psychotherapy; those taking antidepressant medication; or those engaging in 
cardiac rehabilitation or taking any medication for cardiac health including statins, beta-blockers, 
or ace-inhibitors.  Those partaking in any severely restricted diets or exercise programs for CVD 
currently.  
 Methods: Subjects will be randomized to receive treatment in either one-of-four groups: 
cognitive behavior therapy, meditation, acupuncture, or all three treatments, the study will run 
for 16-consecutive weeks.   
Cognitive behavior group: Participants will receive psychotherapy by a licensed 
psychotherapist once-per-week for one hour for a 16-week period.  Psychotherapists treat mental 
disorders with psychological rather than medical means (Mayo Clinic, 2016).  Cognitive 
behavior therapy is one form of psychotherapy in which the psychotherapist helps the patient 
identify unhealthy, negative beliefs and behaviors and replace them with healthy, positive ones 
(Mayo Clinic, 2016). 
Meditation group: Participants will receive group stress-reducing techniques and 
meditation therapy by a licensed meditation practitioner once-per-week for 16-weeks.  
Meditation can produce a state of deep relation for the patient, and is often practiced to reduce 
stress and anxiety.  The practice of meditation involves a focused attention on a conscious 
elimination of negative and “jumbled” thoughts that may be causing stress.  Meditation is 
recognized for producing an enhanced emotional and physical wellbeing through relaxed 
breathing, focused attention, a quiet setting, and a comfortable position (Mayo Clinic, 2017).   
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Acupuncture group: Participants will receive one-hour of Traditional Chinese Medicine 
Acupuncture by licensed or certified acupuncturists who will be instructed to use the same 
meridian points for targeting depression and cardiovascular disease—for all patients.  Patients 
will receive one-hour of acupuncture each week for 16-weeks. Subjects in the all-three 
treatments group will receive all three treatments (cognitive behavior therapy, meditation 
therapy, and acupuncture) for 16-weeks at the same rate and times as subjects in the other three 
experimental groups.   
Information on sex, age, weight, body mass index (BMI) and education level will be 
gathered at the initiation of the study.  BMI for all participants will be obtained using a 
bioimpedance scale which is used to measure the percentage of body fat in relation to lean body 
mass.  A comprehensive lipid panel to assess cardiovascular health will be performed for all 
patients at baseline and following 16-weeks of non-pharmacologic treatments.  Biomarkers of 
cardiovascular disease should include total cholesterol, LDL cholesterol, HDL cholesterol, 
triglycerides, homocysteine, apolipoprotein B, lipoprotein A (lipoprotein subfractions), C-
reactive protein, insulin, HbA1C, and fasting glucose.  Information from subjects on chest pain 
frequency, chest pain duration (minutes), and chest pain severity on a scale of 1-10, will also be 
gathered at baseline and at 16-weeks.  Blood pressure readings will be performed for all 
participants at baseline and after 16-weeks.  Non-pharmacologic therapies should be provided 
once-per-week for a 1-hour period by licensed health care professionals instructed on a standard 
treatment protocol for all subjects.  
Testing for mental health will be administered at baseline and following 16-weeks of 
non-pharmacotherapy for all four groups.  Scores from the Patient Health Questionnaire-9 (PHQ-
9), Beck Depression Inventory (BDI), and the Hamilton Rating Scale for Depression (HRSD) 
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will be gathered and analyzed for any changes in mental health in subjects. The Cardiac 
Depression Scale will also be administered to measure depression in cardiac patients and will be 
provided at baseline and following 16-weeks of non-pharmacotherapy to assess any changes or 
improvements in depressive symptoms among participants in all four groups.  Urinary 
neurotransmitter testing (UNT) for serotonin and dopamine using monoamine assays will be 
administered at baseline and after 16-weeks of treatment (Hinz, Stein, Trachte, & Uncini, 2010).  
Results of UNT for serotonin and dopamine will be compared for changes or improvements, and 
whether they correlate to improvements in self-reported depression severity in the PHQ-9, BDI, 
and HRSD following 16-weeks of therapy.  A comprehensive fatty acids test will also be 
administered to patients at baseline and following 16-weeeks of therapy.  The comprehensive 
fatty acids test provides levels of over 30 markers and total levels of saturated, monounsaturated, 
polyunsaturated, omega-3, omega-6, eicosapentaenoic acid, docosahexaenoic acid, gamma-
linolenic acid and other fatty acids using 2 mL of collected serum following a 24-hour fasting 
period where no alcohol is consumed (The Great Plains Laboratory, Inc., n.d.).  Lipid panel 
levels and depression scale scores will be administered and analyzed for all subjects at baseline 
and at the completion of 16-weeks of therapy for all groups.  
At the conclusion of the study, results of non-pharmacotherapy treatment on patients with 
comorbid depression and cardiovascular disease will be assessed to determine the extent of the 
effects of cognitive behavior therapy, meditation, and acupuncture, or all three therapies, on 
depression and cardiovascular disease in patients.  Close analysis of any changes in scores on the 
Health Questionnaire-9 (PHQ-9), Beck Depression Inventory (BDI), the Hamilton Rating Scale 
for Depression (HRSD), and the Cardiac Depression Scale at baseline and at the completion of 
the study should help determine the effects of cognitive behavior therapy, meditation, and 
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acupuncture on depression.  Meanwhile, lipid panel levels for total cholesterol, LDL cholesterol, 
HDL cholesterol, triglycerides, homocysteine, apolipoprotein B, lipoprotein A (lipoprotein 
subfractions), C-reactive protein, insulin, HbA1C, fasting glucose, and comprehensive fatty acids 
will be assessed for cardiovascular health status.  Any changes in chest pain frequency, chest 
pain duration (minutes), and chest pain severity on a self-reported scale of 1-10 should help 
determine whether cognitive behavior therapy, meditation, and acupuncture, or all three therapies 
combined, have a positive influence on cardiovascular health.  Subjects with comorbid 
depression and cardiovascular disease should be analyzed for any improvements with non-
pharmacologic therapies by assessing all scores on tests for both depression and cardiovascular 
disease.    
Conclusions: the proposed future study might help to determine the effects of non-
pharmacotherapy, including psychotherapy, meditation, acupuncture, or all three therapies, and 
their influence on comorbid major depressive disorder and cardiovascular disease.  If results of 
the study indicate positive effects of these forms of non-pharmacologic therapy on comorbid 
depression and cardiovascular disease, a multimodal and integrative approach to treating 
depression and cardiovascular disease may be the key for the proper diagnosis, management, and 
treatment of these leading health disparities.  Since depression and cardiovascular disease have a 
graded and bidirectional relationship, the successful alleviation of one condition should lead to 
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